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ABSTRACT 
 
The advent of molecular “-omics” technologies enabled an unprecedented view into the 
inner molecular mechanisms of cancer and enhanced optimism towards a patient-tailored 
vision of medicine. The successful application of these molecular approaches in the 
discovery of candidate biomarker has accelerated the shift towards personalization of 
medicine. Indeed, biomarkers hold great promise for refining our ability to establish early 
diagnosis and prognosis, and to predict response to therapy. The develoment of clinically 
useful biomarkers would be impossible without access to human biological specimens and 
associated patient data, since they complete the molecular information gained from 
laboratory research. Furthermore, with the advances of sensitive molecular technologies, 
human bio-specimens can be now successfully used for wide analysis at all molecular 
levels (DNA, RNA and proteins), in addition to conventional cytologic and histologic 
investigations. 
However, despite the hundreds of reports on tumor markers, only a few markers have 
proven clinically useful. The insufficient experience in clinical application of molecular 
methods combined with the high complexity of clinical material represent the major 
obstacles for the development of clinically useful biomarkers. 
Thanks to the possibility to have access to the fresh and archival samples from the hospital, 
our laboratory can investigate the potential of technological innovations and the current 
technical pitfalls directly on clinical material. The work in my thesis is strictly correlated to 
this activity. In particular, the first part is focused on the technical optimization of 
molecular methods for gene expression analysis in biological fluids and especially in urine 
samples. In this context we validated a new experimental kit for total RNA extraction from 
urine samples and tested the potential of a colorimetric approach for PCR product 
detection. The major part of the study is focused on the technical optimization of molecular 
methods for gene expression analysis in archival material. This activity is in step with one 
of the main objectives of the European project called “Archive tissues: improving 
molecular medicine research and clinical practice-IMPACTS”, in which my laboratory and 
other 20 European centres are directly involved. In this phase the comparison of the 
experiences between laboratories and their active collaboration are essential for a more 
rapid validation of protocols dedicated to RNA (but also DNA and protein) analysis. In 
particular, we investigated some molecular aspects involved in the pre-analytical phase 
(tissue fixation procedures) and analytical phase (RNA extraction, RNA quantification and 
integrity assessment, qRT-PCR) of tissue processing. 
 
The final objective of this activity will be the definition of common technical guidelines 
for a reliable quantification of molecular biomarkers for diagnosis, prognosis and therapy 
directly in human archival samples. Finally, my thesis includes the clinical application of 
molecular methods for the quantification of candidate biomarkers in two archival case 
studies (a breast cancer and an adrenal gland cancer case study). In the breast cancer case 
study we showed that a panel of seven genes (involved in different cell pathways) is 
associated to patients’ survival. The adrenal gland tumor case study is part of a preliminary 
study about the angiogenetic process in rare human cancers.  
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LIST OF ABBREVIATIONS 
 
 
ACTB: Actin, beta 
AKT3: Protein Kinase b, gamma  
AMV: Avian Myeloblastosis Virus Reverse Transcriptase 
ATP5B: ATP synthase, H+ transporting, mitochondrial F1 complex, beta subunit 
BTA: in vitro immunoassay for the qualitative detection of bladder tumor antigen in urine 
CDC25a: Cell Division Cycle 25a  
CDK2, CDK4, CDK6: Cyclin-Dependent Kinase 2,4,6 
CK8, CK20: Cytokeratin 8, 20 
Ct: threshold cycle 
DPD: dihydropyrimidine dehydrogenase 
ELOSA: Enzyme-Linked Oligosorbent Assay 
EGFR: Epidermal Growth Factor Receptor (ERBB1,HER1) 
ERK1: Mitogen-Activated Protein Kinase 1 
ER: Estrogen Receptor 
FLT-4: Fms-Like Tyrosine kinase 4 (VEGFR3) 
FFPE: formali-fixed paraffin-embedded tissue 
GAPDH: glyceraldehyde-3-phosphate dehydrogenase 
HER2: v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (ERBB2) 
HKG: housekeeping gene 
HPRT: Hypoxanthine Guanine Phosphoribosyltransferase 1 
hTR: human Telomerase RNA 
hTRT: human Telomerase Reverse Transcriptase 
IHC: Immunohistochemistry 
k-RAS: Kirsten Murine Sarcoma Virus 2 
MGB probe: 3’-minor groove binder-DNA (TaqMan) probe 
MMLV: Moloney Murine Leukemia Virus Reverse Transcriptase 
MVD: Vascular Microvessel Density 
NM23: Non-Metastatic cells 1  
NMP22; Bladder Tumor Antigen (NMP22) Test Kit 
p16: Cyclin-Dependent Kinase Inhibitor 2A  
PI3K: Phosphatidylinositol 3 kinase 
qRT-PCR: quantitative reverse transcriptase-polymerase chain reaction (realtime) 
RAF-1: v-RAF-1 Murine Leukemia Viral Oncogene Homolog 1  
RB: Retinoblastoma 
RB2: Retinoblastoma 2  
RT-PCR: reverse transcriptase-polymerase chain reaction 
SEL-1L: Suppressor of Lin12-Like 
TP: Thymidine Phosphorylase 
TS: thymidylate synthetase 
VEGFC: Vascular Endothelial Growth Factor C 
VEGFD: Vascular Endothelial Growth Factor D 
VEGFR2: Vascular Endothelial Growth Factor Receptor 2 
 
 
Introduction 
INTRODUCTION 
 
Translation of molecular techniques to clinical application is one of the more demanding 
steps for molecular medicine, as reported from the major world organizations working in 
this field as FDA (Food and Drug Administration, http://www.fda.gov) in the States and 
IMI (Innovative Medicine Initiative, http://imi.europa.eu/index_en.html) in Europe. 
This fact is connected with a high number of factors and bottlenecks. Especially he 
availability of human tissues and the huge complexity of these tissues heavily affect the 
efficiency of the methods used in molecular analysis. 
 
1. TOWARDS MOLECULAR MEDICINE  
“Molecular medicine” is commonly referred to a rapidly growing multidisciplinary field. It 
deals with the problem of using the molecular methods to study the disease processes at the 
cellular and molecular level. These molecular information will be used to promote health 
and prevent, diagnose, cure and treat diseases. The inter-exchange of molecular and 
clinical records between researchers and clinicians is critical to fully realize this vision.  
In clinical cancer research it has been recently seen an acceleration towards molecular 
medicine to solve the limitations deriving from the standard diagnostic approaches and the 
progressive decrease of new drug introduction (Phillips et al., 2006).  
Conventional diagnostic and prognostic approaches for human tumors are currently based 
on a combination of histopathology and immunohistology, closely connected with clinical 
data. This strategy, in most cases, provides precise information on tissue origin, tumor 
type, stage and grade as well as information on the completeness of surgical tumor removal 
(Dietel and Sers, 2006). An international classification system based on these conventional 
approaches has been established, the UICC-TNM system (Sobin, 2003). However, because 
of the different molecular features of tumor cells, two patients harboring the “same” type 
of tumor with “identical” stage could show different clinical outcome with respect to 
survival and therapy response. Since the histopathological classification is not sufficient to 
predict the outcome in these cases, new techniques are being developed to better describe 
the clinical behaviour of the different neoplasms.  
A patient-specific disease prediction based on tissue examination would be extremely 
useful to improve this unsatisfactory situation.  
Pitfalls in conventional diagnostic approaches are also reflected in the reduced 
development of successful anti-cancer drugs. In the last decade indeed the number of drugs 
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per year submitted for FDA approval has dramatically declined in comparison with the 
expenditures for the pharmaceutical research as reported in Fig. 1. Many drugs fail because 
are tested in inappropriate patient populations or setted  with unreachable clinical endpoint 
(Kelloff et al., 2004). The main reason for this is related again to the molecular differences 
in the same type of tumor, in fact the same kind of therapy could not be equally successful 
in all affected patients. To treat the cancer more effectively new molecular tools have to be 
included in the diagnosis and prognostication. 
 
 
 
 
 
 
 
 
 
Fig. 1: trends in major drug and biological products submissions to FDA and concomitant expenditures 
(taken from Goldberg, R., Pitts, P. (2006) “The critical path to drug development-A working paper for the 
21th century FDA task force”) 
 
Recent technical advances in “-omics” molecular sciences (genomics, epigenomics, 
proteomics..) through their application in human clinical samples (cells, tissues, fluids) 
have further accelerated the progress towards molecular medicine. 
The precious molecular information, combined with clinical data included in medical 
records, could be used to discover the molecular features of neoplastic disease as well as to 
determine the most powerful biomarkers that may predict disease outcome, prognosis or 
progression and increase the relevance of tissue-based examinations by integrating these 
technologies into standard diagnostic procedures. 
Finally, the definition of successful biomarkers will play a crucial role in a more rapid 
development of more effective and patient-designed drugs, also referred as personalized 
medicine. 
 
2. MOLECULAR MEDICINE IN HUMAN CLINICAL SAMPLES 
Recent progress in the field of molecular biology, genetics and pathology presents 
extraordinary research opportunities to better understand the molecular bases of diseases 
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and for subsequent prevention and treatment. This progress would be impossible without 
access to human biological specimens and associated patient data.  
Specifically, in molecular medicine research human specimens can be used to:  
• Identify novel therapeutic targets for drug discovery (such as specific genes or gene 
products)  
• Identify the molecular pattern of normal cells and cells in various stages of disease 
progression 
• Develop biomarkers for diagnostic and prognostic purposes included surrogate 
endpoints for efficacy studies and clinical trials  
• Define group of patients based on their genetic characteristics and likelihood of 
positive response, for new drugs testing. 
• Define group of patients based on the “biomarkers” of their disease to determine which 
treatment is appropriate  
Human clinical samples used for research may be obtained from autopsies, from patients or 
from healthy people. Some human material is donated by volunteers specifically for 
research (e.g. blood sample), but tissues removed during surgical treatment and surgical 
left overs can also be useful sources.  
There are two main categories of human material that can be used in molecular medicine 
research: biologic liquids and tissue specimens. 
2.1 Biological liquids: body fluids (serum, plasma..), proximal fluids (urine, cerebrospinal 
fluid, pleural effusion, ascites..) and feces are low invasive material sources. They are 
commonly used in cytologic studies and in molecular analysis from a variety of tissues 
(Rifai et al., 2006). They can be used for identification studies and for clinical prospective 
validation studies. Blood is the preferred material for a final diagnostic test (more than 100 
protein-detecting assays are being used in diagnostics now) but complexity of plasma 
proteome and the relatively low abundance of candidate biomarkers makes protein 
discovery largely unsuccessful (Rifai et al., 2006).  Many factors, such as tissue type, time 
of collection, containers used, additives, transport, extraction and analysis of data must be 
considered to ensure the quality of the samples and the reliability of the subsequent 
analyses (Holland et al., 2003). 
2.2 Tissues: fresh-frozen and archival tissues can be used both for histologic analysis and 
for molecular studies on DNA, RNA and proteins. The recent introduction of the laser 
capture microdissection (LCM) has greatly increased the reproducibility and accuracy of 
the molecular analyses on these samples because it offers a rapid and precise method of 
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isolating and removing specific cells (normal, peritumoral, tumoral as an example) from 
complex tissues (Aoyagi et al., 2003; Shi et al., 2003). 
Fresh tissues are the golden source for prospective molecular analysis because of the 
intactness of macromolecules. The use of these specimens is mandatory in microarray-
based gene expression profiling, where high quality RNA is essential. 
On the other hand, formalin-fixed and paraffin-embedded tissues (FFPEs) are a valuable 
resource for retrospective diagnostic and investigative studies. FFPE is the most widely 
available material for clinical retrospective studies. In combination with the potential of the 
new molecular techniques on nucleic acids, these tissues represent an invaluable resource 
for elucidation of disease mechanism and validation of gene expression pattern as novel 
therapeutic targets or prognostic indicators. The main importance of paraffin embedded 
tissues is that all bioptical, surgical or autopsy tissues are routinely fixed, paraffin 
embedded and stored in Pathology department archives for decades. Another advantage in 
employing these tissues is that the procedures of formalin fixation and paraffin embedding 
are similar in most of the hospitals all over the world. These facts give evidence of the 
importance of this type of tissues in studying rare diseases and for retrospective analyses. 
Paraffin embedded tissues allows also to reach a large number of human tissues with any 
kind of lesion without the need of a research specific collection (see Table 1). 
The use of paraffin embedded tissues could be the solution for quantitative analysis in 
clinical samples with long follow-up periods. This new methodology that has been 
developed by our group could be an important tool for detecting reliable indications on the 
expression of genes and correlations among them that could be useful also for therapeutical 
purposes.  
Given the wide availability of the paraffin-embedded tissue blocks along with the clinical 
histories of the patients, both common and rare disease can be studied retrospectively; 
furthermore, the cell architecture and morphology are excellently preserved, which is a 
prerequisite for exact histopathological diagnosis.  
Nevertheless, molecular studies still have some limitations, due to extensive degradation of 
macromolecules before and during formalin fixation (Macabeo-Ong et al., 2002).  
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 FFPE TISSUES FRESH-FROZEN TISSUES 
Number High number Limited number 
Clinical 
information 
Retrospective long-term 
clinical information 
Often short-time clinical 
information only 
Morphology High level Low level 
Microdissection Accurate Less accurate 
Variability range Representative of large 
clinical variation 
Low level of variability for 
the limited number of cases 
Follow-up Very long Often very short 
DNA Degraded, but can be 
analyzed 
Very well preserved 
RNA Degraded, but can be 
analyzed 
Very well preserved 
Proteins Cross-linked Very well preserved 
         
 Table 1: comparison between FFPE and fresh-frozen tissues 
 
3. METHODS FOR DNA, RNA AND PROTEIN ANALYSIS 
Fueled by the complete genomic data acquired from the Human Genome Project and the 
clinical need of comprehensive analytical tools to study the cancer biology, the “-omics” 
technologies (high-throughput methods) started to join the more conventional molecular 
approaches (low-throughput methods), accelerating the discoveries in clinical cancer 
research (Chung et al., 2007). These discoveries include mechanistic understanding of 
cancer biology as well as the identification of biomarkers supporting molecular 
classification of tumors, early detection, prognosis, treatment response and clinical 
outcome. 
With the advances in these high-throughput “-omics” technologies, human bio-specimens 
can be successfully used for wide analysis at all molecular levels (DNA, RNA and 
proteins) (Table 2). In particular, technologies such as DNA microarrays and tissue arrays, 
analyzing large number of variables simultaneously and in great detail, have moved from 
hypothesis-based to successful discovery-based research, in which large quantities of data 
can be analysed in a single experiment without a specific hypothesis (Canevari et al., 2006; 
Ransohoff, 2004).  
Furthermore, the association of these technologies to the innovative laser-capture 
microdissection procedure allows selective analysis of DNA, mRNA or proteins from 
precise locations within a tumour and thereby allows the definition of the molecular pattern 
specific for the malignant cells. Microdissection for example enhanced expression 
profiling of breast (Wulfkuhle et al., 2001) and ovarian cancer (Jones et al., 2002). 
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FUNCTIONAL  GENOMICS EPIGENOMICS PROTEOMICS METABOLOMICS GENOMICS 
IHC Sequencing MSP Northern blot NMR Low thr. western blot Southern blot Cobra RPA PET immunoprecipitation 
CGH microSAGE ELISA LC/MS Mid thr. MethyLight FISH RT-PCR Mass spectrometry SKY qRT-PCR 
PCR Protein arrays microarrays 
MALDI-TOF HPLC-PDA mCGH TMA High thr. microarrays GC-MS genomic array SELDI RLGS analysis 2D gel 
 
Table 2: comparative throughput of  molecular approaches 
 
The advent of innovative molecular techniques did not supplant the traditional approaches, 
on the contrary, they still represent precious tools for molecular investigation in clinical 
cancer research. 
The following list summarizes the conventional and the new promising methods for DNA, 
mRNA and protein analysis. 
 GENOMICS: the comprehensive evaluation of the genetic changes in cancer gives the 
possibility of developing diagnostic/prognostic markers and tools. PCR-based approaches, 
FISH (in situ hybridization) (Strefford et al., 2001) and CGH (Kallioniemi et al., 1994) are 
technologies dedicated to the identification of either large or small deletions, 
translocations, duplications of a given gene as well as regions of amplification. Recently 
the high resolution microarray comparative genomic hybridization (mCGH) (Wang et al., 
2004) was developed, this technique enables a high throughput assessment of changes in 
DNA sequence number at higher resolution without using metaphase chromosomes. 
Another important advance in cytogenetics has come through the use of spectral 
karyotyping (SKY) analysis (Veldman et al., 1997), which has increased the accuracy of 
classification of rearrangements and translocations. 
 EPIGENOMICS: CpG islands are found in promoter regions of about half of the 
cellular genes and are normally associated with gene silencing. As a consequence of the 
aberrant DNA methylation patterns found in cancer cells, these epigenetic modifications 
could be important targets for the development of new therapies and specific approaches to 
reverse silencing of tumor suppressor genes or other genes involved in drug response in 
cancer patients.  
There are three main strategies for methylation detection: the digestion of DNA by a 
methylation-sensitive or -insensitive restriction endonuclease; the chemical modification of 
DNA by sodium bisulfite [MSP (Herman et al., 1996), COBRA (Xiong and Laird, 1997)] 
and immunoprecipitation of 5-methylcytosine. Recently, all three approaches have been 
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coupled to high-throughput technologies [realtime PCR (Trinh et al., 2001), microarrays 
(Ching et al., 2005) and  restriction landmark genome scanning (Hatada et al., 1991)]. 
An alternative detection platform is MALDI-TOF mass spectrometry, which can read a 
single nucleotide at very high throughput (Jurinke et al., 2004). 
 miRNAomics: in recent years, further levels of biological complexity have been 
identified: one of them is miRNAome, which represent the milieu of non coding RNAs 
that is in part responsible of gene expression regulation. Among human diseases, it has 
been shown that miRNA are aberrantly expressed in cancer, suggesting that they could 
play a role as a novel class of oncogenes or tumor suppressor genes (Takamizawa et al., 
2004). Recently, with the development of dedicated micorarrays the entire miRNAome has 
been analysed and the feasibility of human cancer profiling has been demonstrated in 
different oncotypes (Lu et al., 2005). 
 FUNCTIONAL GENOMICS: Northern blot or RNase protection assay (RPA) are not 
the most suitable approaches for gene expression analysis in biological samples as they are 
not sensitive enough and require large amounts of intact RNA. The PCR-based techniques, 
which detect even small quantities of degraded RNA, has allowed determination of single-
transcript expression levels of known markers as well as of additional markers in tissues 
and circulating cancer cells, serum, urine etc (Woude et al., 2004). The further progress in 
realtime chemistry has improved sensitivity, reproducibility and reliability of gene 
expression analysis. 
The field of functional genomics has developed rapidly due in part to microarray 
technology, which allows the expression analysis of thousands of genes in a given tissue 
sample in a single experiment (gene expression profiling).  
This technique made possible the identificaction of gene subsets expressed in B-
lymphocytes which are able to predict aggressiveness of large B-cell lymphomas and the 
patient survival (Shipp et al., 2002). Similarly a gene expression profile has been identified 
for good prognosis breast cancer patients (van de Vijver et al., 2002). Furthermore, SAGE 
technique (Velculescu et al., 1995) is capable of measuring global gene expression values 
even from minute amounts of mRNA [micro-SAGE (Datson et al., 1999)]. 
 PROTEOMICS: proteomics refers to the comprehensive study of proteins including 
detection, identification, measurement of protein concentration, detection and 
characterization of modifications, characterization of protein-protein interaction and 
regulation. Conventional methods such as ELISA, IHC, Western blot and 
immunoprecipitation, are limited by the evaluation of single proteins at the time, but they 
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are still the standard assays for the detection of well known serum markers such as 
carcinoembryonic antigen (CEA), human chorionic gonadotrophin, alfa feto protein 
(HCGA) and prostate specific antigen (PSA). They are now joined by other large-scale 
technologies [tissue and protein microarrays (Kononen et al., 1998), 2D-mass 
spectrometry approach (Gygi et al., 2000), SELDI (Seibert et al., 2004)] that enable the 
simultaneous detection of proteins in a single experiment (protein expression profiling). 
 METABOLOMICS: both gene expression and protein activity have consequences in 
metabolic profile (metabolome). Molecular imaging methods (PET, NMR) have been 
applied to patients’ serum as a potential novel strategy for early ovarian cancer detection 
(Odunsi et al., 2005), and to in vitro cell lines to identify candidate biomarkers as clinical 
diagnostic indicators. Much work have been published employing mass spectrometry (gas 
chromatography-mass spectrometry, high performance liquid chromatography-mass 
spectrometry(Dunn et al., 2005) 
These techniques can directly follow the path and quantitative changes of an administered 
molecule or the molecule’s target, allowing the study of drug distribution and 
pharmacokinetics. As a consequence they could discriminate between responders and 
nonresponders to a given drug.  Imaging can also play a key role in measuring response to 
therapy (angiogenesis responsiveness, cell apoptosis, resistance to chemotherapy) (Woude 
et al., 2004). 
 
Even if the above-cited methods have generated an interesting list of candidate biomarkers, 
their functions are not still clearly related to tumor progression needing to be validated.  
Obstacles in the concrete use of these methodologies for  biomarker discovery are due in 
part to the current limited accession to human specimens and to biobanks. Indeed, these 
data repositories would represent the concrete interface between tissue donors and 
scientists performing biomedical research; however their development is still faced with 
many ethical, legal, scientific challenges. 
Technical reproducibility and standardization processes are expected to be performed 
directly on clinical material, which can only be achieved by the interdisciplinary 
communication and collaboration among molecular biologists and pathologists. 
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4. BIOMARKERS 
The concrete application of innovative molecular methods to cancer clinical practice and to 
personalized medicine is expressed by the identification of molecular markers 
(biomarkers).  
 
4.1 Definition of biomarker 
Biomarkers represent the key for translating the molecular characteristics detectable at the 
DNA, RNA or protein level, in “characteristics that are objectively measured and evaluated 
as indicators of normal biological processes, pathogenic processes, or pharmacological 
responses to a therapeutic intervention” -Biomarker Definitions Working Group (2001)-.  
Molecular markers hold great promise for refining our ability to establish early diagnosis 
and prognosis, and to predict response to therapy. This information will be finally used at 
critical decision points throughout drug discovery, screening, preclinical testing and all 
phases of clinical testing. 
The use of biomarkers in clinical practice can be fully realized only through a strong 
collaboration between laboratory research and clinics as it requires a continuous 
interchange of clinical and molecular information between scientists and pathologists. This 
cooperation is essential in all steps of biomarker analysis, from laboratory detection to final 
validation. 
 
4.2  Types of biomarkers 
Genomic and proteomic technologies have significantly increased the number of potential 
DNA, RNA and protein biomarkers under investigation, allowing their detection both in 
human fresh frozen/archival tissues and in biological liquids.   
In body fluids DNA, RNA and proteins can be detected either as free circulating 
biomarkers or as indicators for the presence of circulating cancer cells.  
- DNA: circulating DNA and tumour cells were among the first markers evaluated for 
cancer staging. Increased serum DNA concentrations are associated with cancer and 
circulating tumour cells in the blood or bone marrow with systemic metastasis (Hoon et al., 
2000; Kahn et al., 2004; Muller et al., 2005; Sidransky, 2002). 
Mutations in oncogenes, tumour-suppressor genes, and mismatch-repair genes, and 
chromosomal and microsatellite instability can serve as DNA biomarkers (Kobayashi et 
al., 2005; Launonen et al., 2000; Zhu et al., 2003).  
Epigenetic regulation of transcription and translation (histone deacetylation, lysine-specific 
histone-H3 methylation, and promoter region CpG methylation) can also be important in 
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carcinogenesis. Pharmacogenomic effects of methylation silencing, with implications for 
choice of therapy, have also been shown (Esteller et al., 2000; Palmisano et al., 2000; 
Rosas et al., 2001; Yamaguchi et al., 2003). To our knowledge, epigenetic factors have not 
yet been used in formal staging, but their application to predict response to treatment can 
be expected in the future (Esteller, 2005). 
Particular single-nucleotide polymorphisms have been associated with increased cancer 
risk (Bonnen et al., 2002; Chang et al., 2003a; Hoque et al., 2003; Janne et al., 2004), but 
SNPs are not currently used for formal cancer staging and grading. 
RNA- : as for DNA, also RNA markers can be evaluated individually (Bonin et al., 2008; 
Bonin et al., 2006; Siracusano et al., 2005), even though many high-throughput 
technologies have been developed to assess mRNA expression comprehensively. Most 
RNA-based biomarkers undergoing clinical evaluation consist of multi-gene molecular 
patterns or 'fingerprints'. Although such patterns can be more accurate than single-
molecule markers, the choice of the genes to include in the pattern efforts the problem of 
the statistical complexity, prompting new developments in biostatistics, bioinformatics and 
data visualization.                    
Expression profiling has been associated to differences in survival, prognostic capability, 
predicted response to neoadjuvant therapy, prediction of metastasis in lymph-node 
negative patients (Bittner et al., 2000; Chang et al., 2003b; Ramaswamy et al., 2003; 
Sotiriou et al., 2003; van de Vijver et al., 2002). The transcriptional levels of enzymes have 
been used pre-clinically for predicting the response to chemotherapy (Rosell et al., 2004; 
Salonga et al., 2000). Extensive validation studies will be required to transfer those 
developments from clinical research to standard practice in staging. In fact these and other 
RNA-based markers have not yet undergone rigorous, prospective clinical validation and 
they have not still been approved by the FDA.                                 
- Proteins: as quantity by itself might not be the salient parameter for protein biomarkers, 
molecular tests for protein detection focus more on the cellular location and on protein 
function that depends on post-translational modifications such as phosphorylation or 
glycosylation (Godovac-Zimmermann and Brown, 2001; Nishizuka et al., 2003). Recently 
protein expression profiling has joined the individual protein detection (Liotta et al., 2003; 
Matikainen et al., 1999): this high-throughput expression analysis may outperform DNA 
and RNA profiling as these profiles do not necessary correlate with protein expression, 
while protein is the ultimate reflection of gene function (Zhang et al., 2004). These 
approaches however remain in the developing stage.                                - 
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Circulating cells: epithelial cancer cells are easily detectable in blood using specific cell 
surface markers (cytokeratins). They have been found to correlate with disease status and 
in patients with liver (Yang et al., 2008) and breast cancer (Cristofanilli et al., 2004), 
suggesting their use as biomarkers for drug response and disease progression (Beerepoot et 
al., 2004). In addition to fully differentiated endothelial cells, immature circulating 
endothelial progenitor cells derived from bone marrow also exhibit potential as a surrogate 
marker for tumor angiogenesis (Woude et al., 2004).  
4.3  Biomarker discovery  
DNA, RNA and proteins represent the targets of biomarker research. The first step that 
allows identification of candidate biomarkers is the discovery process. It can be based on 
model systems or different human biological materials. The design of this research and is 
usually a simplified, binary comparison between diseased and normal samples.  
Human cell lines are genetically homogeneous systems providing an important source for 
basic research biomarker discovery as they are powerful tools to describe many cellular 
processes. However, the use of clinical specimens is in any case necessary to completely 
characterize molecular alterations involved in human diseases (Gillespie et al., 2002). 
Research that proposes the use of human cell lines available from the American Type 
Culture Collection or a similar repository is not considered human subject research because 
the cells are publicly available and all of the information known about the cell lines is also 
publicly available.  
The molecular research on disease-associated clinical samples is the best tool to discover 
the genetic basis of neoplastic disease as well as to find out the biomarkers. The flow of 
this reseach can take two directions (Fig. 2). The first direction, from the laboratory bench 
to the patient’s bedside, is taken by the translational research that acts to turn the laboratory 
data into novel therapeutics and diagnostics. The second opposite direction, from the 
patient’s bedside to the laboratory bench, corresponds to molecular analysis/reverse 
translational research that interrogates clinical samples for a variety of  biomolecules. 
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Fig. 2: Illustration of the circular flow connecting the lab bench to the bedside (adaped from Molecular 
Profiling Initiative by the National Cancer Institute and the Center for Information Technology) 
  
 
The products of this phase are lists of  candidate biomarkers that can be supplemented with 
(or substituted with) candidates drawn from the literature (Rifai et al., 2006). 
 
4.4  Biomarker validation 
Depending on the purpose of the biomarker, the objective of the validation –such as 
specificity, sensitivity, and reproducibility of assays for diagnostic purposes- will be 
different. 
In any case, it is possible to define common steps from discovery to validation. After 
biomarker discovery, a qualification step is necessary. First, it confirms that the candidate 
biomarker observed in discovery is seen using alternative methods. Second, qualification 
confirms the candidate biomarker in simplified comparisons of diseased and normal human 
bodily fluids, if discovery was not initially performed in this material. In this phase, 
sensitivity is usually emphazised over specificity (Rifai et al., 2006). In verification step, 
the analysis is extended to a large number of samples, now incorporating a broader range 
of cases and controls with their environmental, genetic and biological variations. Thus in 
verification of candidate biomarker, sensitivity is affirmed and specificity begins to be 
assessed. The few candidate biomarkers that perform well in verification then move 
through assay optimization to validation, in which a research grade of the final assay is 
tested against many samples that precisely reflect the full variation of the targeted 
population. 
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In all these steps the correct acquisition and interpretation of molecular data and the proper 
collection of clinical material are essential to accelerate the process. 
Table 3 reports the cancer biomarkers that have been approved by FDA for their clinical 
use. Most of them are single proteins, and the majority of these protein biomarkers has 
been detected in serum (Ludwig and Weinstein, 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: US Food and Drug Administration-approved cancer biomarkers. See (Ludwig and Weinstein, 
2005). 
 
4.5  Biomarkers in oncology drug development 
The application of biomarkers in the field of molecular targeted cancer therapies can be 
seen as the final goal of molecular medicine.  
Indeed, biomarkers have many potential uses in all phases of the drug development 
process, from target discovery and validation through pivotal clinical trials for drug 
registration (Park et al., 2004). Biomarkers can also be used to screen and optimize 
candidate agents, enhance mechanistic understanding of drug or drug combinations, 
identify optimal target populations and predict response, resistance and toxicity (Park et 
al., 2004).  
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It is clear that the translation of the molecular insights into useful therapeutic approaches is 
highly complex as traditional paradigms of drug development are not well suited to these 
new challenges and may not fully exploit the potential of molecular advances. Instead, an 
integrated and collaborative effort is needed among pharmaceuticals, biotechnology and 
clinics to translate laboratory insights into rationally designed agents (Ransohoff, 2004). 
The first step in the application of 
biomarkers in drug development is 
considering their impact on the 
evaluation to therapeutic 
intervention. When a biomarker is 
likely to predict clinical benefit or 
risk, it may achieve the status of surrogate (“to substitute for”) endpoint. In this 
circumstances, this biomarker is able to substitute the corresponding clinical endpoint that 
the conventional diagnostics normally uses in the assessment of a specific therapeutic 
intervention- Biomarker Definitions Working Group (2001)-. 
BIOMARKER: a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic 
intervention 
CLINICAL ENDPOINT: a characteristic or variable that reflects 
how a patient feels, functions or survives 
SURROGATE ENDPOINT: a biomarker that is intended to 
substitute for a clinical endpoint. It is expected to predict clinical 
benefit based on epidemiologic, therapeutic, pathophysiologic, or 
other scientific evidence 
Although all surrogate endpoints can be considered biomarkers, only a few biomarkers will 
achieve surrogate endpoint status. The use of surrogate endpoints to establish therapeutic 
efficacy in registration trials is an established concept that has been addressed in regulation 
that enables FDA to grant accelerated marketing approval for certain therapeutics. 
Some FDA approved anticancer agents highlight the success of using biomarkers in 
oncology drug development and demonstrate how biomarkers with strong clinical 
validation provided compelling targets for therapy (see Table 4). 
 
 
 
 
 
 
 
 
 
 
 
Table 4: US Food and Drug Administration-approved anti-cancer drugs (Papadopoulos et al., 2006). 
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However, despite high interest and investments in this field, few novel biomarkers are 
effectively introduced in the clinical practice every year (Rifai et al., 2006). Many agents, 
despite promising scientific rationale, have shown disappointing efficacy in clinical trials, 
or clinical studies have revealed benefit in some trials but not others (Park et al., 2004). 
The reasons for this disjunction reflect the long and difficult path from candidate 
biomarker discovery to the clinical assay and the lack of coherent and comprehensive 
guidelines for biomarker development (Anderson, 2005). 
 
5. EXAMPLES OF CLINICAL APPLICATION OF MOLECULAR METHODS IN 
HUMAN SAMPLES 
In this chapter, two examples of clinical case studies are reported. The first neoplasia to be 
considered is breast cancer. It’s very frequent in industrialized countries 
(http://www.cancer.gov/). Many reports about new candidate biomarkers in these cancers 
have been published so far. 
The second cathegory of human cancers involves the adrenal gland. It can be affected by 
rare tumors that involve both the adrenal cortex than the inner medullary part. Due to their 
rarity, few studies succeeded in characterizing them from a molecular point of view 
(Stratakis, 2003). 
 
5.1 Breast carcinoma 
Breast cancer is the leading cause of death among women in developed countries 
(Yankaskas, 2005). Despite important advances in therapy, more than half of the affected 
patients undergo relapses (Paredes et al., 2007). Several clinical and pathological factors 
have been proposed to predict the recurrence of breast cancer. However, at the present time 
it is not possible to predict recurrence versus no recurrence at an individual level. It is 
commonly accepted that the different clinical courses of patients characterized by the same 
histology and stage are the result of molecular differences among cancers. Different single 
molecular markers have been assessed in the past 20 years, but failed to be considered for 
clinical use for various reasons (Pusztai et al., 2006). Microarrays studies for example have 
identified expression profiles and gene sets that are prognostic or predictive (van de Vijver 
et al., 2002) but comparison of the lists of genes derived from these studies shows only a 
slight overlap probably due to differences in the cohorts of patients, microarray platforms 
and mathematical methods of analysis (Fan et al., 2006). 
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The selective detection of expression level of a well-defined panel of genes involved in the 
maintenance/abrogation of the cell senescence machinery should represent a valid 
alternative hypothesis-based approach that allows to investigate the progression of breast 
carcinoma using archival material. 
 
5.2 Adrenal gland tumor 
Adrenal gland cancers are rare tumors (approximately 1 out of 1 million people worldwide 
develop adrenal cancer for unknown causes) that can affect both the adrenal cortex and the 
inner medulla and are characterized by the production and secretion of excessive amount 
of hormones. 
Adrenocortical tumors, that arise from human adrenal cortex, represent a group of 
heterogeneous lesions that produce excess secretion of steroid hormones and aldosterone. 
Most are benign adenoma, but in rare occasions they can progress to carcinoma, which is 
characterized by a highly aggressive behaviour (Sidhu et al., 2003). Often the progression 
towards malignancy is diagnoseable only in presence of a clear evidence of local invasion 
and metastasis. 
Pheochromocytoma is a rare tumor that in 90% of cases originates from the adrenal glands' 
chromaffin cells, causing overproduction of catecholamines (Bravo, 1994). Approximately 
10% of pheochromocytomas are malignant. One of the main difficulties in its menagement 
is the absence of reliable criteria for distinguishing malignant from benign tumors. 
Adrenal gland, as well as other endocrine organs, requires physiologically adequate 
vasculature to promote  access of hormones products to circulation. It is suggested that a 
different angiogenetic pattern might also condition the secretory status of these adrenal 
cancers. Several experimental and clinical studies showed that cancer growth and its 
metastatic spread are closely related to angiogenesis (Ellis and Fidler, 1996). This 
association is based on studies that have evaluated the tumor angiogenic phenotype, 
including microvessel density (MVD) (Bono et al., 2002; de Jong et al., 2000) and the 
expression level of angiogenic factors (VEGFs) (Kurahara et al., 2004; Mohammed et al., 
2007). VEGFC and VEGFD and their receptor VEGFR2 seem to have a crucial role in 
vasodilatation, endothelial cell migration and proliferation in blood vessels (Risau, 1997). 
VEGFC and VEGFD are also ligands of  FLT-4 (Achen et al., 1998; Joukov et al., 1996), 
where they seem to be important regulators of lymph vessels growth and also enhancers of 
lymphatic metastasis in different tumors (Mandriota et al., 2001; Stacker et al., 2001).  
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Due to the rarity of these adrenal gland tumors, few studies in the literature have 
comprehensively evaluated the angiogenetic process and its role in the molecular 
characterization  of these cancers. 
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 AIM OF THE STUDY 
 
The aim of the study was to define which are the most appropriate molecular methods for 
gene expression analysis in clinical practice.  
In order to explore the potential of  conventional and innovative molecular approaches in 
clinical cancer research, two main biological fields were considered: biological liquids and 
archival tissues. 
 
1. BIOLOGICAL LIQUIDS: in this part of the study we focused on the use of urine 
samples for mRNA biomarker detection and tried to optimize some molecular approaches 
dedicated to this type of analysis.  
 
2. ARCHIVAL TISSUES: Most part of this project of thesis is connected to the work that 
is performed in our laboratory about application of molecular approaches in archival 
tissues.  
This part of the work in fact is developed in the context  of  the European project called 
“Archive tissues: improving molecular medicine research and clinical practice-
IMPACTS”. This project involves the collaboration of many researchers in our laboratory 
and in other 20 centres spread in 11 European countries. This complex and multilaboratory 
project gives reason of the different experiences that I developed in these last three years. 
My work, in fact, must be combined with that of many other researchers that are involved 
in other parts of this project.  
In this part of the study, we explored several home-made molecular approaches that can 
limit the use of archival tissues for gene expression analysis in clinical practice and 
investigated the potential of some technological innovations. The optimization of these 
molecular approaches involved in pre-analytical (tissue transport, fixation time, type of 
fixative..) and analytical (RNA extraction, qualitative and quantitative RNA detection..) 
treatment of  archive material was performed in both human cell lines and clinical samples. 
In this context we analyzed 2 examples of clinical application of molecular methods in 
breast and adrenal gland cancer to detect quantitatively specific mRNA biomarkers.
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MATERIALS AND METHODS 
 
1. SAMPLE COLLECTION 
The clinical samples can be divided in two groups. The first one includes human cancer 
cell lines (A375, T24), various formalin-fixed paraffin-embedded samples of different 
origin and human urine samples, that were used for technical optimization experiments. 
The second group includes  two indipendent clinical case studies from archival tissues that 
were used to study candidate biomarkers. 
 
1.1  Samples for technical optimization 
- A375 (malignant melanoma) cell line was used for technical optimization in archival 
tissues, while T24 (transitional cell carcinoma) cell line was used for technical 
optimization in urine samples. Cells were cultured at confluence in 150mm plates in RPMI 
medium supplemented with 10% fetal calf serum. After trypsinization the cell pellet was 
washed twice in PBS and the cell count was performed using a conventional Burker 
chamber. Pellets were then submitted to following analysis (RNA extraction or fixation). 
- Voided urine samples from bladder cancer patients and non tumoral controls were 
provided by the Department of Urology of Cattinara Hospital of Trieste; they were used for 
the optimization of methods for gene expression analysis in biological fluids.  
-  Clinical formalin-fixed and paraffin-embedded samples deriving from breast, adrenal 
gland and colon cancer archived in the Cattinara Hospital of Trieste were collected from 
case studies analyzed in our laboratory and were used for the optimization of methods for 
gene expression analysis in archival tissues.  
 
1.2  Breast cancer case study 
To investigate the progression of breast carcinomas, we have analysed the level of 
expression of a well-defined panel of genes involved in the maintenance/abrogation of the 
cell senescence machinery in primary breast cancers.  
Eighty women resident in the Northeastern Italian province of Trieste, whose first primary 
cancer was unilateral invasive breast carcinoma, were selected from the data base of the 
Surgical Pathology Department of the University of Trieste. Seventy-three patients 
belonging to this cohort were also part of a previous study (Bonin et al., 2006). Cancers 
were diagnosed at the age of 34 or older, between 1971 and 1989, and only treated with 
Halsted radical mastectomy and complete axillary dissection. Carcinomas were 
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histologically graded according to Elston and Ellis (Elston and Ellis, 1991) and grouped in 
stages according to the TNM Classification of Malignant Tumours, 6th edition (Singletary 
et al., 2003). Clinical information is reported in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Characteristics of the 80 breast carcinomas by stage, grading and patients age at diagnosis 
 
The cohort of women was followed through the general popμlation-based Friμli-Venezia 
Giμlia Cancer Registry  from diagnosis of breast cancer to death or 31 December 2006. 
During the observation period, 69 women died and all of them underwent complete 
autopsy at the Surgical Pathology Department of the University of Trieste.  
Formalin fixed paraffin embedded specimens from primary breast cancer were used to 
isolate and quantify the RNA. RNA was then submitted to gene expression investigations.  
 
1.3  Adrenal gland tumor case study  
To elucidate the role of angiogenesis and lymphangiogenesis in aggressiveness and 
progression of different types of adrenal gland cancers, formalin-fixed and paraffin 
embedded samples from 15 adenomas, 9 carcinomas and 10 benign pheochromocytomas 
between 2000 and 2006 were chosen. Such 34 patients were selected from the data base of 
the Surgical Pathology Department of the University of Padova (Table 2). 
 
 
 
 
 
 
 
Table 2: Characteristics of the 34 adrenal gland tumors by grading and patients age at diagnosis 
 
GRADING Years of age at 
diagnosis STAGING 
G1 G2 
N° of 
cases 
G3 Mean Range 
I 14 15  4 33 65 38-79 
IIA  7 14  5 26 63 35-87 
IIB  1  4  1  6 56 48-63 
IIIA  3  6  2 11 57 34-76 
IIIC  0  3  1  4 70 47-90 
All stages 25 42  13 80 61  34-90 
GRADING Years of age at 
diagnosis TUMOR 
G1 G2 
N° of 
cases 
G3 Mean Range 
ADENOMA - - - 15 56 31-77 
CARCINOMA 2 2 3 9 49 37-66 
PHEOCHROM. - - - 10 44 23-61 
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Formalin fixed paraffin embedded specimens were used to isolate and quantify the RNA. 
RNA was then submitted to gene expression investigations.  
 
2. HISTOLOGIC REVISION, MICRODISSECTION AND IHC 
- For hematoxylin-eosin (H&E) staining 3μm-thick sections were cut and mounted on a 
glass slide. The standard staining procedure was followed (Melis, M., “Compendio di 
tecnica istopatologica”, Lombardo Editore, 1975) and analysis of the morphological aspect 
was performed by a pathologist. 
- When both peritumoral (or normal tissue) and tumor tissue were present on the same 
paraffin block, or when the peri-tumoral component was also necessary for the following 
molecular analysis, manual microdissection was performed.  
Areas for microdissection were first marked on the original hematoxylin-eosin-stained 
slide and then a manual microdissection was performed by sectioning directly the paraffin 
block. 
- Immunohistochemistry (IHC) was performed on tissue sections when histopathological 
analysis was required to confirm the molecular resμlts.  
Specifically for adrenal gland tumor case study, immunohistochemistry using the anti-
CD31 (Ventana Medical System) was performed in order to determine the microvessel 
density (MVD), which is an index of angiogenetic pattern (Hlatky et al., 2002; Pusztaszeri 
et al., 2006). 
Briefly, for every specimen two consecutive 3μm-thick sections were dried at 60-65°C for 
1hour. Immunohistochemical detection was achieved on an automated immunostainer 
(Ventana Medical System) according to the manufacturer’s protocols. 
CD31-stained sections were evaluated for MVD by two indipendent investigators. 
Each section was first scanned at low-power magnification (10x-25x) to select the areas 
containing the highest number of capillaries and small venules (neovascular “hot spots”); 
three hot spots were selected and evaluated at 250x field  (ocular lens, 10x; objective lens, 
25x; field area, 0.74mm2). This was made in order to include the maximum number of 
microvessels. Single immunoreactive endothelial cells, or endothelial cell clusters, with or 
withour lumen and separate from adjacent structures, were counted as individual 
microvessels.  
MVD was calculated as the average of the three counts.  
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3. MOLECULAR METHODS FOR GENE EXPRESSION ANALYSIS IN URINE 
This part was dedicated to the technical optimization of molecular methods for gene 
expression analysis in biological fluids, especially in urine. The research was focused on 
the investigation of alternative molecular approaches that could substitute the more 
expensive (realtime PCR), time-consuming (Chomczynski and Sacchi extraction protocol), 
hazardous (radioactive-based detection protocols) procedures in clinical practice.  
 
3.1  Technical optimization 
In this section the applicability and reliability of several molecular approaches for gene 
expression analysis in urine were tested. Both a cell line (T24) and voided urine samples 
were used. 
3.1.1  RNA extraction: Total RNA from T24 cell line was used for this experiment. RNA 
was extracted by means of .the Chomczynski and Sacchi protocol (Chomczynski and 
Sacchi, 2006), with some modifications, and by means of a spin column-based 
experimental kit, in order to compare sensitivity and efficiency of the 2 methods.  
The kit was developed in our laboratory through a collaboration with a company devoted 
to the molecular diagnostics (R&D Lab of Macrochip, Trieste, Italy). This kit is an 
experimental vacuum-based system that allows a rapid filtration and collection of the cells 
on a filter membrane. The filter is then directly incubated in the lysis solution and RNA 
extraction is the performed using a spin-column based protocol. In this kit, the colums is 
filled with diatomaceous earth (consisting fossilized diatoms, a type of hard-shelled algae) 
that, in the presence of highly concentrated chaotropic agents, is able to selectively retain 
the RNA. 
For this comparison experiment five 2-fold dilutions of T24 cell line were used, starting 
from 2*106 cells. Each quantity was previously resuspended in 50ml PBS (to reproduce the 
conditions of cells as they were in 50ml of urine) and two parallel protocols were followed. 
The test was repeated three times in the same conditions. 
- According to the first protocol, the T24 cell samples in PBS were centrifuged at 1200g 
and the cell pellet resuspended in 500μl of digestion solution (“D solution”: 4M 
guanidinium thiocyanate, 25mM sodium citrate, pH 7.0, 0.5% N-lauroylsarcosine  and 
0.1M 2-mercaptoethanol). RNA extraction was performed by adding to this solution an 
equal volume of an acid phenol/chloroform 50:50 mixture. The upper, acqueous phase was 
recovered and RNA was overnight precipitated by adding 3 volumes of absolute ethanol 
and 14.5μl glicogen 1mg/ml. Total RNA was resuspended in 15μl DEPC H 0. 2
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Quantification and quality determination of total RNA was performed by 
spectrophotometer reading at 260nm and 280nm. Purified RNA was stored at -80°C.  
- According to the second kit protocol, the T24 cell samples resuspended in PBS were 
filtered through a vacuum filter system. Cells were collected on a filter membrane, put 
directly into 450μl of lysis solution for 30’ (4M guanidinium thiocyanate, 25mM sodium 
citrate, 0.5% N-lauroyl sarcosine). The filter could be stored at this point of the extraction 
at -20°C for a maximum period of 1 month. One-hundred μl of 4% diatomaceous earth in 
potassium acetate were added to the lysis solution and was loaded on the spin column. 
After a cycle of washings, the bound RNA was eluted in a fixed volume of 50μl of pre-
heated DEPC H20. All the procedure required 1 hour of work. Quantification and quality 
determination of total RNA was performed by spectrophotometer reading at 260nm and 
280nm. Purified RNA was stored at -80°C.  
3.1.2  Quantitative end-point PCR: an end-point PCR was used for the quantification of 
the mRNA transcriptional levels instead of the realtime PCR in order to keep low the costs 
of the research. 
Before reverse transcription step, a DNase treatment was performed to remove 
contaminating gDNA from RNA solution. 2μg of total RNA were resuspended in 1x 
DNaseI Buffer, 80 units of Rnase inhibitor (Ambion), 10 units of DNaseI (Amersham). 
Reaction was left to proceed at 37°C for 20 minutes. To purify RNA from DNaseI an 
extraction with phenol-H20/chloroform was carried out. RNA was precipitated with 
isopropanol using 5μl glycogen 1mg/ml as a carrier. Quantification of total RNA was 
performed again and purified RNA was stored at -80°C.  
Three target genes were tested: hTRT, CK20 and CD4, which present highly variable 
levels of expression in urothelial cells. To correct for errors depending on differences in 
sample to sample RNA quality, GAPDH expression was introduced as normalization 
factor. 
For every target gene intron-spanning primers and a probe were designed in order to meet 
specific criteria of length (between 15 and 25 bases), G/C content (around 50%), similar 
melting temperatures, low self-primer and hetero-primer formation, amplicon length 
(between 60 and 90 base pairs). The specific genes studied and the corresponding 
oligonucleotide sequences are described in Table 3 (Siracusano et al., 2005). The specific 
probes were then used for PCR product detection using two alternative approaches (see  
3.1.3). 
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For all the tested genes optimal annealing was defined as the temperature (T°a) 5°C below 
the lower of the PCR primer melting temperatures; optimal hybridization was defined as 
the temperature (T°hybr) 12-15°C below the melting temperature of the probe. 
Optimal conditions of amplification were determined experimentally for each mRNA 
target sequence by reverse transcribing and amplifying equivalent amounts of RNA over 
various cycles of the PCR and by reverse transcribing and amplifying dilutions of RNA 
over the same number of PCR cycles (Stanta et al., 1998c).  
Table 3 describes the optimal conditions in terms of starting amount of RNA and number 
of cycles for every tested gene. 
 
 
Table 3: primer/probe sequences, length of the amplicons and optimal PCR and hybridization conditions .  
 
Total RNA was reverse transcribed in a final volume of 10μl using AMV-RT associated 
with the reverse specific primer.  
RT solution contained 1x AMV-RT buffer, 1mM dNTPs, 15pmol of specific reverse 
primer, 2 units AMV-RT, 4 units Rnase inhibitor and total RNA to a final volume of 10 μl. 
The reaction took place at 42°C for 60’.  
The whole reverse transcription product was used as a template for the PCR reaction.  
Amplification was performed in a final volume of 50μl by adding 5μl of the 10x PCR 
buffer (500 mM KCl, 100 mM Tris pH 8.3, without MgCl2), 15pmol specific forward 
primer and 2.5units Taq Polymerase. The solution was denatured for 3’ at 94°C, subjected 
to 5 cycles of 1’ at 94°C, 1’ at the specific annealing temperature of the primer pair and 1’ 
at 72°C followed by a variable number of cycles of  30” at 94°C, 30” at the specific 
annealing temperature of the primer pair and 30” at 72°C. 
 
PCR AND HYBRIDIZATION 
CONDITIONS 
GENE OLIGO SEQUENCES 
PCR ng RNA Length T°a T°i cycles for RT 
Sense: CCAAGGTCATCCATGACA 
GAPDH 90bp 50°C 40 50°C Antisense: CATCCACAGTCTTCTGGGT 50ng 
Probe:ACTGTGGTCATGAGTCCTTCCACGA 
Sense:CAAGGCTGGGAGGAACAT 
hTRT 90bp 55°C 45 50°C Antisense: AGGCTGTTCACCTGCAAAT 150ng 
Probe: CTGTGACACTTCAGCCGCAAGACC 
Sense: GGCGTCATCATGAATGAA 
CK20 Antisense:CAGAACTGCAGTCTGTCTCT 100bp 52°C 45 46°C 500ng 
Probe:AAGGTTCTTCTGGGCCATGACTTCA 
Sense: CGGCAAGGCCACAATGAA 
300ng CD4 Antisense: TTTCCCTGAGTGGCTGCT 90bp 55°C 45 50°C 
Probe: GCAGCACCAGAAGCAAGTGCCTA 
 24
Materials and Methods 
3.1.3 PCR product detection: for PCR product detection two different methods were 
compared: dot-blot hybridization with a radiolabelled probe and a colorimetric approach 
with a phosphorilated probe, that could reduce the risks connected with the use of 
radioactive material. 
- According to the first protocol, 20μl of each amplification product were first mixed with 
30μl of 20x SSC denaturing solution and then spotted on a positively-charged 
nitrocellulose membrane. Membrane was air-dried and crosslinked. Probes (see Table 3) 
were radiolabelled with γ32P-ATP using T4 polynucleotide kinase, while membrane was 
pre-hybridized at T°hybr  in a 6x SSC solution containing 0.5% milk-powder.  Hybridization 
was performed by adding the probe solution and incubating the membrane overnight. 
Washings were performed in progressively stringent conditions using SSC and 0.1% SDS. 
Membranes were kept in contact overnight with a radiosensible plate and the radioactive 
signal was detected by the Cyclone instrument. The expression levels were quantified as 
counts per minute (cpm) by the software. 
- The second quantification approach, an ELISA-like method called ELOSA (Enzyme-
Linked Oligosorbent Assay), was performed using commercial 96-well NucleoLink Strips 
from Nunc as a support. The protocol used was an adaptation of the suggested DIAPOPS 
procedure (Detection of Immobilized Amplified Products in a One Phase System) as  
amplification was performed in solution and following hybridazion was carried out using 
the immobilized probe. 
Plates were first prepared according to the manufacturer’s instruction. Briefly, for each 
gene forward primers and probes described in Table 3 were ordered with some 
modifications: the forward primer was 5’-biotinilated and the probe was 5’-phosphorilated 
(see Table 4). PCR reaction of the target genes was run as above-mentioned (3.1.2). Probes 
were covalently linked to the well surface by a carbodiimide mediated condensation by an 
incubation at 50°C for 5 hours.  
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 GENE PRIMER SEQUENCES 
 Sense: b*-CCAAGGTCATCCATGACA 
GAPDH Antisense: CATCCACAGTCTTCTGGGT  Probe:P^-ACTGTGGTCATGAGTCCTTCCACGA 
Sense:b-CAAGGCTGGGAGGAACAT  hTRT Antisense: AGGCTGTTCACCTGCAAAT 
Probe:P- CTGTGACACTTCAGCCGCAAGACC  Sense: b-GGCGTCATCATGAATGAA 
CK20 Antisense:CAGAACTGCAGTCTGTCTCT  Probe:P-AAGGTTCTTCTGGGCCATGACTTCA 
Sense: b-CGGCAAGGCCACAATGAA  
CD4 Antisense: TTTCCCTGAGTGGCTGCT 
Probe: P-GCAGCACCAGAAGCAAGTGCCTA  
Table 4: optimal hybridization conditions in the ELOSA approach. 
*b, biotinilated; ^P, phosphorilated. 
 
After blocking of non specific sites, amplification products were denatured and incubated 
with the specific probe at 50°C for 2 hours. A streptavidin-alkaline phosphatase complex 
and the PNPP substrate (p-Nitrophenyl Phosphate, Disodium Salt) were then added. After 
incubation for 30’ the colorimetric reaction was detected by an ELISA reader. The 
expression level values were read at 405nm and were expressed as optical density (OD) 
values. 
Optimized quantity of probe and amplicon were defined for each target sequence 
combining different quantities of probe (50, 100, 250, 500, 750ng per well) and PCR 
product (5-10μl per well) using 3 urine samples that showed variable expression levels of 
the considered genes. 
The dynamic range of the detection reaction was tested using progressive dilutions of a 
previously amplified PCR product corresponding to each target sequence. Briefly, a PCR 
product corresponding to each tested gene was run on an agarose gel, the bands of interest 
were excised and an electroeluition was performed to purify the products. After 
spectrophotometric quantification, the purified PCR products, expressed as fmoles, were 
diluted to test the linearity conditions of each of the four systems. 
In order to compare this colorimetric quantification method with the radiolabelled probe-
based detection, a parallel quantification with both methods was performed using a panel 
of 20 urine samples (showing variable expression levels for the target genes) and 
expression values, expressed in cpm and OD, were compared. 
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4. MOLECULAR METHODS FOR GENE EXPRESSION ANALYSIS IN 
ARCHIVAL TISSUES 
In the second part we we performed a gene expression analysis in two indipendent 
formalin-fixed and paraffin-embedded case studies.  
 
4.1 Technical optimization 
In this part of the study limits and potential of several technical approaches for gene 
expression analysis were explored to optimize their application in human archival tissues. 
Depending on the optimization protocol, either archival tissue specimens or cell line-based 
model system were used (in the latter case some slight modifications were applied to the 
protocols to adapt them to the cell line system). 
3 differently expressed housekeping genes were chosen to perform this comparative 
analysis: ACTB (high expression) ATP5B (intermediate expression) and HPRT (low 
expression). 
Primer sequences resulted from a Custom Gene Expression Assays previously used in 
combination with TaqMan chemistry (see Table 5).  
 
Gene Primer sequences Length 
 Sense:CGGCCCCTCCATCGT    ACTB 66bp 
Antisense: AAAGGGTGTAACGCAACTAAGTCAT  Sense: AAGGCAGGGAGACCAGACT  ATP5B 89bp 
Antisense:GCCTTCTGTACCATCCATAGCAATA   
Sense: GTGTCATTAGTGAAACTGGAAAAGCA  HPRT 91bp 
Antisense:CGATGTCAATAGGACTCCAGATGTT   
Table 5: Primer sequences used in optimization experiments 
 
4.1.1 Starting procedures 
The following list describes the standard procedures that were used as reference protocols 
for the technical comparison with other protocols dedicated to gene expression analysis. 
They were defined on the basis of the procedures that we commonly use in our laboratory, 
combined with the experience reported in the literature. These protocols were tested both 
on cell lines (A375) and FFPE sections. When cell line was used, protocols were slightly 
adapted. 
4.1.1.1 Fixation: fixation is a critical step for tissue preservation. Formalin is the most 
used fixative as, although toxic, it is able to preserve many tissutal components. This 
fixative was used as the reference solvent. Tissue fixation was performed in 4-10% 
buffered formalin immediately after removal. Fixation time depended on the tissue 
dimensions but usually takes a maximum of 24 hours. The volume of formalin was almost 
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20 times the volume of the tissue (Melis, M., “Compendio di tecnica istopatologica”, 
Lombardo Editore, 1975). 
4.1.1.2 RNA extraction: a proteinase K-based protocol to extract RNA from 6-8μm 
human tissue histological sections was used (Stanta et al., 1998b). Proteinase K action is 
essential to free the RNA that is trapped in the protein matrix produced by formalin. 
For every paraffin embedded block ten 6-8μm-thick histologic sections were 
deparaffinized with xylene and rehydrated with ethanol. When the peritumoral component 
was necessary, a manual microdissection was performed by sectioning the paraffin block 
and collecting the two components in two separate tubes. 
Samples were then digested in 150-400μl of proteinaseK 6mg/ml diluted in RNA digestion 
buffer (1.12 M Guanidine thiocyanate, 20 mM Tris HCl pH 7.5, 0.5% N-Lauroyl 
Sarcosine, 40 mM β-mercaptoethanol) at 45°C overnight. Total RNA was isolated by acid 
phenol/chloroform extraction followed by ethanol precipitation. Total RNA was 
resuspended in the appropriate volume of DEPC H20 (between 15 and 30μl, depending on 
the amount of starting tissue). Purified RNA was stored at -80°C.  
4.1.1.3 RNA quantification: spectrophotometer reading is the most common 
quantification approach of total RNA. 1-2μl of each sample were diluted in 500μl H2O and 
absorbances at 260, 230 and 280nm were acquired using the Amersham GeneQuant 
instrument. The formula derived from the Beer-Lambert law was used to determine total 
RNA concentration at 260nm, while the 260nm/230nm and 260nm/280nm ratios were used 
to evaluate the level of contamination (by co-purified organic compounds, phenol, 
proteins…) of the RNA solution. 
4.1.1.4 RNA integrity assessment: the evaluation of the degradation levels of RNA is 
important as they can affect the outcome of the subsequent gene expression analysis. The 
denaturing 1% agarose gel electrophoresis (followed by ethidium bromide staining) is the 
most commonly used procedure to assess RNA integrity. 5μg of each RNA were loaded on 
the gel.  
After the run, the gel was checked under the UV light and the clear presence of two main 
bands, corresponding to 28S and 18S rRNA, was considered an index of intact RNA; the 
presence of a smear or the absence of these bands was defined as an index of RNA 
degradation. 
4.1.1.5 DNase treatment: this treatment is essential to completely remove the 
contaminating genomic DNA from the RNA solution prior RT-PCR amplification. It 
results even more important if the target mRNA presents pseudogenes at DNA level or 
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primers set are not intron-spanning. For each formalin-fixed and paraffin embedded sample 
4μg of total RNA were digested in 1x DNaseI  Buffer and 10 units of DNaseI. Reaction 
was incubated for 15’ at 25°C.  
Enzyme inactivation was performed by heating the RNA solution for 10’ at 65°C with the 
addition of 2μl of 25mM EDTA. Concentration of the new RNA solution was determined 
taking into account the spectrophotometric reading before treatment and the new final 
volume of reaction. 
4.1.1.6  Reverse transcription: this step is one of the major sources of variability in gene 
expression analysis. As “reference” procedure for cDNA synthesis a MMLV-based 
reaction was used (Godfrey et al., 2000). Briefly, 800ng of total digested RNA were 
reverse transcribed in a final volume of 20μl using 250units MMLV reverse transcriptase 
in the manufacturer’s buffer (Invitrogen) containing 40units RNase inhibitor, 250ng 
random hexamers, 4.5mM MgCl2, 1mM dNTPs and 10mM DTT. The reaction was carried 
out at 37°C for 60’, followed by 70°C for 15’ and 4°C for 5’. 
4.1.1.7 Quantitative realtime PCR: the realtime-based approach was chosen for gene 
expression analysis because it allows a more sensitive detection of PCR products, is more 
reproducible and offers a higher dynamic range od detection. Real-time quantitative RT-
PCR analyses for ACTB, ATP5B and HPRT were performed in the MasterCycler ep 
RealPlex (Eppendorf) using the SybrGreen approach.  
In order to optimize the performance of each assay (in terms of efficiency of amplification, 
sensitivity, primer-dimer formation, nonspecific sequence production), T° annealing, T° 
denaturation, primer concentration and fluorescence reading temperature were adjusted 
(see Table 6), using a standard curve for each tested sequence. To this purpose, intact 
cDNA from A375 cell line was amplified and cloned into the TopoVector using the TA 
cloning Kit (Invitrogen). Efficiency and linear range of amplification were checked setting 
up a serial dilutions of this standard DNA, ranging from 106-107 to 102-10 
molecules/reaction: each dilution was PCR amplified and the recorded Ct values plotted 
against the log of the dilution. A linear regression line was fitted through the points and 
efficiency was defined as 10^(-1/slope) (Rasmussen, R.P. 2001. Quantification on the 
LightCycler, p.31-34.In "Rapid Cycle Real-time PCR, Methods and Applications.Springer 
Press, Heilderberg. ) (Table 6) 
Optimal conditions of amplifications were then used for construction of standard curves 
with 5-fold fixed serial dilutions of  the sample cDNA (40ng-64pg cDNA).  
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For simplicity we supposed that reverse transcription yield was 100% and ng of cDNA 
corresponded to ng of input RNA. All reactions were run in duplicate. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6: optimal realtime PCR conditions for SybrGreen chemistry approach determined by standard curve 
run using a cloned sequence. 
No MgCl2 optimization  was necessary because the PCR buffer is specially formμlated to auto-adjust it. 
Optimal T°a, primer concentration and reading temperatures were defined by melting curve analysis. 
 
Standard curves were analysed according to the general guidelines proposed by Nolan et 
al. (Nolan et al., 2006). As a reproducibility limit of the replicates an SD <0.5 was 
considered as acceptable and the limits of the dynamic range of the amplification were 
considered in order to define the range of dilution values in which the standard curve was 
linear. The threshold cycle (Ct) was then determined with the support of the “Noiseband” 
software (provided by Eppendorf). This algorithm was used for automatic determination of 
the threshold (here threshold is 10 times the standard deviation above the noise of the 
baseline); the optimum baseline (“noise” from the background fluorescent signal) was 
defined manually for each sample. The baseline fluorescence and the threshold were 
automatically associated to a Ct (threshold cycle) value (see the example of a standard 
curve reported in Fig.1). The Ct value of the first or second dilution of the sample was then 
used for the following comparative gene expression analysis since these values where 
always within the linear range of the standard curve. It was considered reliable only when 
efficiencies between samples and genes were similar; a maximum of 10% of mismatch was 
tolerated.  
 
 
 
 
 
 
 
REALTIME CONDITIONS 
GENE 
T°a T° den. Primer conc. 
Reading 
T° 
R2 efficiency Dynamic 
range 
ACTB 60°C 95°C 300nM 77°C 107-102 0,998 99% 
ATP5B 60°C 93°C 300nM 80°C 107-102 0,995 98% 
HPRT 62°C 96°C 300nM 74°C 108-103 0,995 98% 
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 Threshold 
 
 Baseline 
 
 
 
 Efficiency  
 Coefficient of 
determination  
 
 
 
Fig. 1: example of a standard curve obtained from a 10-fold dilutions of cloned ATP5B sequence. Analysis 
performed by MasterCycler ep RealPlex Software. (SybrGreen chemistry). 
 
PCR was performed in the RealMasterMix SYBR ROX buffer (5 PRIME) using cDNA 
template/plasmid standard DNA, 1x SybrGreen (5 PRIME) and forward and reverse 
primers at the defined optimal concentration in a 25-50μl-final reaction mixture. The 
solution was then splitted in the required number of replicates. Samples were denatured at 
95°C for 1’30”, and the following general program was used: 45 cycles of denaturation at 
the defined denaturation temperature for 30”, annealing at the optimal temperature for 30”, 
extension at 72°C for 30” and reading for 30”; additional extension at 72°C for 10’; default 
melting curve program (95°C for 15”, 60°C for 15”, linear temperature transition to 95°C 
at 0.1°C/second, 95°C for 15”). 
 
4.1.2 Compared procedures 
In this part the “reference” protocols described in 4.1.1 are compared with other 
procedures that often are reported in literature as methods for gene expression analysis in 
archival material. 
4.1.2.1 Fixation: a A375 cell line-based homogeneous 
model was used to compare over time the effects of 
formalin against two other fixatives on RNA quality and 
quantity. The protocol was slightly modified to be applied 
to this cell line-based model. 
The following alcoholic fixatives were used: neutral 
buffered formaldehyde 10% (NBF), a home-made methacarnoy (60% methanol, 30% 
chloroform and 10% glacial acetic acid) and FineFix, a new commercial alcohol-based 
fixative (Milestone). 
 FIXATION 
 RNA EXTRACTION  
 RNA QUANTIFICATION  
 RNA INTEGRITY ASSESSMENT  
 DNase TREATMENT  
 REVERSE TRANSCRIPTION  
 QUANTITATIVE REALTIME PCR 
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5 fixation times were considered for each fixative, and a mean of 2.5-3x106 cells were 
intended for each time. After count, two aliquots were isolated for direct extraction of 
RNA (to be used as a positive control), the others aliquots, containing the same number of 
cells were pelleted and resuspended in the fixative; the fixation process was carried out for 
1, 3, 6, 12 and 24 hours at room temperature in a rotor. At each determined time, fixed 
cells were pelleted and washed with PBS.  
Total RNA from non fixed cells (about 2.5-3x106 cells) was isolated using 500μl Trizol 
reagent according to the manifacturer’s instructions, and resuspended in 30 μl DEPC H 0. 2
RNA from fixed cells was extracted using the proteinaseK-based protocol for archival 
tissues, with some modifications (see 4.1.1.2  for the original protocol). Briefly, cell pellets 
were well resuspended in 400-500μl of proteinaseK 6mg/ml diluted in RNA digestion 
buffer at 45°C for 3 hours. RNA was isolated by acid phenol/chloroform extraction 
followed by ethanol precipitation. Total RNA was resuspended in 19μl DEPC H20, and 
purified RNA was stored at -80°C. RNA quantification was performed by conventional 
spectrophotometer (4.1.1.3) and integrity was determined by denaturing gel 
electrophoresis. (4.1.1.4). 
2μg of total RNA were treated with DNaseI followed by heat-inactivation (4.1.1.5) and 
800ng of RNA were reverse transcribed using the MMLV-based protocol described in 
4.1.1.6. Expression levels of ACTB and ATP5B were quantitatively analysed by means of 
a SybrGreen-based realtime PCR. A standard curve was run for each fixed and not treated 
sample using five 1:5 dilutions starting from 40ng cDNA and Ct values were defined 
(4.1.1.7). For each fixative and time of fixation, the Ct values (second dilution) of ACTB 
and ATP5B were directly compared. The Ct values of the not-treated cells were used as the 
“golden standard” condition. 
4.1.2.2 RNA extraction: the various protocols associated to this procedure have not been 
investigated yet, but the effects of the time and the temperature of digestion on RNA 
recovery will be soon considered, as defined in the last recent European meeting.. 
4.1.2.3 RNA quantification: the cell line system used for 
the fixation assessment was then used also for comparing 
different approaches for total RNA quantification. 
After cell fixation and nucleic acid extraction by proteinase 
K-based method (see 4.1.2.1), conventional RNA 
spectrophotometric quantification was compared against 
two more recent alternative approaches. The first one was the use of Nanodrop, a new 
 FIXATION 
 RNA EXTRACTION  
 RNA QUANTIFICATION  
 RNA INTEGRITY ASSESSMENT  
 DNase TREATMENT  
 REVERSE TRANSCRIPTION  
 QUANTITATIVE REALTIME PCR 
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sensitive spectrophotometric approach (ND-1000, NanoDrop Technologies, USA), in 
which 1μl of each sample is sufficient to yield a reading value at 260, 230 and 280nm. 
The second one was the use of Agilent Bioanalyzer (Agilent Technologies). This 
instrument employs a fluorescent intercalanting agent to detect RNA concentration. In this 
experiment the Agilent RNA 6000 Nano Kit was used and 1μl of each sample was 
employed. Samples and chips were prepared following the manufacturer’s protocol. The 
coefficient of determination (R2) was obtained comparing the concentration values, 
expressed as ng/μl, obtained with these three methods. 
4.1.2.4 RNA integrity assessment: The cell line 
system (A375) used for fixation assessment was then 
used also for comparing different approaches total RNA 
degradation levels assessment. After cell fixation and 
extraction by proteinase K-based method (see 4.1.2.1), 
total RNA was quantified using spectrophotometric 
reading. The conventional denaturing gel electrophoresis analysis was then compared with 
two alternative methods. 
 FIXATION 
 RNA EXTRACTION  
 RNA QUANTIFICATION  
 RNA INTEGRITY ASSESSMENT  
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- The first approach was the Agilent Bioanalyzer combined with the reagents in the RNA 
6000 Nano LabChip kit. With this microfluidic capillary electrophoresis system three types 
of data analysis were used: the simple electropherogram analysis, the“Ratio method” (we 
defined a 28S/18S ribosomal ratio from 0,7 to 2,5 as an index of good quality RNA) and 
the “RNA Integrity Number (RIN) method” (Schroeder et al., 2006) [we considered values 
equal or greater to 6 to represent good RNA (Strand et al., 2007)]. Smear analysis was also 
performed in order to evaluate the percentage of fragments present in each interval of 
length. 10 intervals were used: 50-100, 50-100, 100-150,150-200, 200-300, 300-500, 500-
1000, 1000-2000, 2000-3000, 3000-4000, 4000-5000 bases. 
- The second approach used an RT-PCR amplification of fragments of increasing length. 
This RT-PCR assay involved the amplification of ACTB mRNA using primers designed to 
amplify 5-6 fragments of progressive length (reverse primer was kept fixed whenever 
possible); the range of fragments was between 77 and 651 bases (Table 7). After DNaseI 
digestion followed by heat inactivation (4.1.1.5). 800ng total RNA were reverse 
transcribed in a final volume of 20μl using MMLV-based protocol (4.1.1.6). PCR reaction 
was carried out using 2μl of each cDNA in a final volume of 25μl containing 2.5μl of the 
10x PCR buffer (500mM KCl, 100 mM Tris pH 8.3, 150mM MgCl ), 15pmol specific 2
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forward and reverse primer and 2.5units Taq Polymerase. Primer design followed the rules 
described in 3.1.2. 
For all the designed amplicons, a common amplification protocol was used: denaturation 
for 3’ at 94°C, 1’ at 94°C, 1’ at the specific annealing temperature and 1’ at 72°C for 5 
cycles,  30” at 94°C, 30” at the specific annealing temperature and 30” at 72°C for the 
optimal number of cycles and 5’ at 72°C as a final extension. Primer sequences and 
optimal amplification conditions were used as previously reported (Stanta et al., 2006). 
RNA integrity was then assessed checking the amplicon bands in a 8% acrylamide gel 
stained with ethidium bromide. 
 
 Gene Primer sequence Length T°a Cycles  
Sense: ATCACTGCCCTGGCACCCA  ACTB 77bp 60 
 
30 Antisense: CCGATCCACACGGAGTACTTG 
Sense:CTGGACTTCGAGCAAGAGAT ACTB  177bp 58 40 Antisense: GAAGGTAGTTTCGTGCATCG  
Sense:CGGGACCTGACTGACTACCT ACTB  291bp 57 45 Antisense: the same primer used for beta actin 170bp  Sense:GTTGCTATCCAGGCTGTGCT ACTB 438bp 57 45  Antisense: the same primer used for beta actin 170bp 
 Sense:GGCATCCTCACCCTGAAGTA ACTB 651bp 58 45  Antisense: the same primer used for beta actin 170bp 
 
Table 7: primer sequences and optimal amplification conditions of beta actin fragments of progressive length 
 
In order to compare the reliability of these methods in the prediction of real mRNA 
accessibility to the subsequent gene expression analysis, total RNA from each fixed and 
not fixed sample was reverse trascribed using again the MMLV-based protocol described 
in 4.1.1.6. The gene expression analysis on ATP5B and HPRT was then performed using 
the SybrGreen-based protocol, as already described (4.1.1.7). Briefly, a standard curve 
(40ng-64pg cDNA) for each fixed and not treated sample was run and Ct values were 
directly compared. 
4.1.2.5 DNase treatment: Optimization of this protocol 
was performed using six different paraffin embedded 
sections from breast cancer samples.  
After proteinaseK-based RNA extraction (4.1.1.2) and 
spectrophotometric quantification (4.1.1.3), the DNase 
digestion followed by heat inactivation (4.1.1.5) was 
compared with the digestion followed by  phenol/chloroform extraction. 
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According to this protocol, 2μg total RNA were resuspended in 1x DNAseI Buffer, 80 
units of RNase inhibitor (Ambion), 10 units of DNaseI (Amersham). Reaction was left to 
proceed at 37°C for 20 minutes. To purify RNA from DNaseI an extraction with phenol-
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H20/chloroform was carried out. RNA was then precipitated with isopropanol using 5ul 
glycogen 1mg/ml as precipitation carrier. Spectrophotometric quantification of total RNA 
was performed again and purified RNA was stored at -80°C.  
800ng of treated RNA with these alternative methods were then reverse transcribed using 
the MMLV-based protocol (4.1.1.6) and the transcriptional levels of ACTB mRNA were 
assessed by means of the SybrGreen-based protocol, as already described (4.1.1.7). 
Briefly, a standard curve (40ng-64pg cDNA) for all the six samples was run in parallel 
after treatment with these two approaches and sensitivity, efficiency and coefficient of 
determination were calculated. 
4.1.2.6 Reverse transcription: Analysis of this protocol 
was performed using a pool of RNA extracted from colon 
cancer formalin-fixed paraffin embedded sections. After 
RNA extraction (4.1.1.2) and DNase digestion (4.1.1.5) 
total RNA was submitted to different cDNA synthesis 
protocols, using the procedure described in 4.1.1.6 as a 
template.  
 FIXATION 
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The comparative protocols used different combinations of reverse transcriptase enzymes 
(MMLV or AMV) and priming strategy (random hexamers, random 15-mers and a mix of 
specific primers) (Table 8). Each RT was run in triplicate. Both random 6-mers and 
random 15-mers were used in two equimolar combinatios: the first one was 
0.167nmol/reaction, and corresponded to what is normally used in literature and in our 
laboratory (Specht et al., 2002). The second one was 3.35nmol/reaction, and corresponded 
to what was recently found in a report (Stangegaard et al., 2006). The cDNA synthesis 
performed using AMV and a “mix” of reverse primers consisted of  a mixture of all the 
specific reverse primers in the same RT solution (“multiplex” reverse transcription). 
12pmol/reaction of each primer were used because they were consistent with the quantity 
of  the forward primer used in the following PCR reaction. Exceptionally for this 
experiment a gene expression analysis of TS (69bp), TP (69bp) and DPD (69bp) was 
performed, in addition to the already used ACTB (66pb). Optimization of reaction 
conditions for each gene were previously determined (data not shown). 
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 PRIMING STRATEGY 
ENZYME 6-mers 15-mers Mix reverse 
primers (nmol/reaction) (nmol/reaction) 
(pmol/reaction) 
   MMLV 
(250units) 
_ 
3.35nmol 3.35nmol 
0.167nmol 0.167nmol 
  AMV 12pmol of each 
reverse primer (4units) 
3.35nmol 3.35nmol 
 
Table 8: schematic representation of the reverse transcription setting using different combinations of 2 
reverse transcriptases associated with different priming strategies. 
 
Each reverse transcription was performed in 20μl using 800ng digested RNA. For MMLV-
based protocols the conditions described in 4.1.1.6 were followed. For AMV-based 
protocol, the RT solution contained 1x AMV-RT buffer, 1mM dNTPs, 12pmol of each 
specific reverse primer or 3.35nmol of random primers per reaction,  4 units AMV-RT, 8 
units RNase inhibitor and total RNA to a final volume of 20 μl. The reaction took place at 
42°C for 60’.  
The reactions containing MMLV and both random primers were carried out at 37°C for 
60’, followed by 70°C for 15’ and 4°C for 5’; the reactions containing AMV were carried 
out at 42°C for 60’. 
Gene expression analysis of ACTB, TS, TP and DPD was performed using the SybrGreen-
based reatime PCR (4.1.1.7). 
Briefly, for every condition tested, sensitivity was evaluated as the mean Ct of the triplicate 
and reproducibility as its standard deviation. The most sensitive and reproducible 
approaches were used for standard curve construction in order to evaluate the efficiency 
and the linear range of RT-PCR. 
4.1.2.7 Quantitative realtime PCR (qRT-PCR): we 
evaluated which was the most reliable approach for 
quantitative gene expression analysis of ATP5B and 
HPRT comparing the SybrGreen method described 
4.1.1.7 to the TaqMan probe chemistry.  
For the comparison between the two procedures, the 
previously described primers were used (Table 5) but for the TaqMan approach further 
internal MGB probes were ordered. For ATP5B: 5’-(6-FAM) CTCTCACCCAAATGCT-
MGB 3’; for  HPRT: 5’-(6-FAM) CAAACTCAACTTGAACTCTC-MGB 3’).  
 FIXATION 
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 RNA QUANTIFICATION  
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The optimal conditions of amplification (T°annealing and MgCl2 concentration) were 
preliminarly determined on a purified cloned sequence containing the target of interest. 
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Ten-fold serial dilutions of 107-108 copies of cloned ATP5B and HPRT were amplified and 
the recorded Ct values were plotted against the log of the dilution. A linear regression line 
was fitted through the points and coefficients of dermination (R2) and efficiencies were 
calculated, as it was performed for SybrGreen chemistry (4.1.1.7) (Table 9). 
 
 
 
 
 
 
Table 9: optimal realtime PCR conditions for TaqMan chemistry approach determined by standard curve run 
using a cloned sequence. 
 
Both methods were then used for testing the expression levels of ATP5B and HPRT genes 
in a panel of six adrenal gland tumors paraffin-embedded samples that were previously 
reverse transcribed using the MMLV-based protocol (4.1.1.6).  
A standard curve (40ng-64pg cDNA) for all the six samples was run in parallel using both 
the SybrGreen and TaqMan probe approaches and a mean value of sensitivity (intended as 
the mean values of the six first dilution Ct values), efficiency and coefficient of 
determination were calculated.  
According to the TaqMan-based protocol, PCR was performed in the ReadyMix Taq 
(Sigma) in a 25-50 μl-final reaction mixture volume containing cDNA template/plasmid 
standard DNA, reference dye (ROX), adjusted MgCl2 and the Custom TaqMan Gene 
Expression Assay (Applied Biosystems); this latter contains an optimized mix of forward 
and reverse primer and a MGB probe labelled with FAM dye. 
Samples were denatured at 95°C for 10’, and the following recommended two-step 
program was used: 45 cycles of denaturation at 95°C for 1’ and annealing/extension at   
60°C for 15”. 
 
4.2 Application of molecular methods to gene expression analysis in two archival case 
studies 
In this second part of the study molecular methods for gene expression analysis were tested 
to detect quantify candidate biomarkers in two clinical case studies. 
The breast cancer case study was collected in order to define if the expression levels of 
some selected genes could have a prognostic role in recurrence (see 1.2 for clinical 
information). 
REALTIME CONDITIONS 
GENE 
T°a [MgCl2] 
R2Dynamic 
range 
Efficiency 
ATP5B 60°C 1.5mM 107-102 0,999 97% 
HPRT 60°C 3mM 108-103 0,998 95% 
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The adrenal gland cancer case study was used to quantify possible candidate biomarkers 
for angiogenetic/molecular characterization of these rare tumors (see 1.3 for clinical 
information). 
Gene expression analysis was performed in both case studies using a quantitative endpoint 
RT-PCR associated to a radiolabelled probe-based dot blot detection approach instead of a 
realtime PCR in order to keep low the costs of the research and to continue with this 
successful line of work in which our laboratory is involved.  
Absolute quantitative PCR is not possible in FFPE because of the variables that could 
affect the efficiency of the amplification. These variables include the type of tissue, length 
of fixation, interval before fixation, age of the paraffin block, size of the section, and the 
amount of extracted DNA or the amount of synthesised cDNA added to the PCR mixture. 
All these factors, and perhaps more, conspire to confound a proportional linkage between 
the final amplification signal and the original amount of target in an absolute 
quantification. The only method to quantify PCR products in formalin fixed paraffin 
embedded materials is a relative quantification. In means that, for a precise comparison, 
the results must be standardized against the quantity of detected housekeeping genes.  
- For both case studies, total RNA extraction was performed using the protocol described 
in 4.1.1.2. Briefly, 6-8 μm-thick tissue slides were collected for each sample and, after a 
paraffinization step, sections were digested at 45°C overnight using the proteinase K-based 
protocol. Total RNA was resuspended in the appropriate volume of DEPC H20 and 
purified RNA was stored at -80°C until use. 
- RNA was then submitted to the quantitative end-point PCR followed by the dot blot 
detection of the PCR products. 
For every target gene intron-spanning primers and a probe were designed in order to keep 
the amplicon shorter than 100bp and to avoid amplification of contaminating DNA (Table 
10-11); the missing sequences have been already described (Bonin et al., 2006; Stanta et 
al., 1998a; Stanta et al., 1999). For all the genes considered, the optimal annealing 
temperature in PCR amplification was defined as the temperature (T°a) 5°C below the 
lower of the PCR primer melting temperatures. For radiolabelled probe-based 
quantification, the optimal hybridization temperature was defined as the temperature 
(T°hybr) 12-15°C below the melting temperature of the probe. 
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 BREAST CANCER CASE STUDY 
 
GENE PRIMER SEQUENCES LENGTH  
 Sense: AAGGCCAACCGCGAGAAGATGA 
ACTB* 74bp  Antisense: TGGATAGCAACGTACATGGCTG 
Probe: CCCAGATCATGTTTGAGACCTTCAACACCC  
Sense: TCTGCCTTGGACTATCTACA  AKT3 93bp Antisense:AATTTTTATGTGGCCATCTCCGTGATCT   Probe: CAAGTTGGAGAATCTAATG 
 Sense: AGGAGAAGCTGAAGCTGGA 
CK8 98bp  Antisense: CTCTGTACGCTTATTGATC 
Probe: GAGGACTTCAAGAACAAGTAT GAG G  
Sense: GTTCCCAAATGCTGACTC  ERK1 91bp Antisense: CAGAGC CTGTTCTACTTCAA  Probe: TGGACAAAATGTTGACATTCAA 
 Sense: CAGAAAGGATTCCGCCTT 
NM-23 85bp  Antisense: GGTCCTTCAGGTCAA CGTA 
Probe: CATGCAAGCTTCCGAAGATCTTCTC  
Sense: CCAAAATTACTGCTGTCAAT  PI3K 79bp Antisense: TAGGCCAAATCTGAAGCA 
 Probe: GATGTTGCTCAGCTTCAGGCGC 
 Sense: GGCAGCAGTGATAGCAGA 
p130  101bp  Antisense: AAGGTGCTGCTTGACCTC 
Probe: CTGGAGTCTCTACTGGTTCTATCTTTG  
Sense: GGATTGGGTCAGGCTCTT  RAF-1  85bp Antisense: GGGTCGACAACCTTTAGGA 
 Probe: TAAATGGCACGGAGATGTTGCAG 
 Sense: TTCTAGAGTCTCCAAATCCAG 
SEL-1L 92bp  Antisense: ATGTGCTGTGCCTTCAAT 
Probe: GTACGGAAACCAGCTTTGACCG  
Table 10: primer/probe sequences and length of part of the sequences used in the breast cancer case study. 
The others can be found in previously published papers (Bonin et al., 2006; Stanta et al., 1998a; Stanta et al., 
1999). * HKG chosen for expression data normalization 
 
 
 ADRENAL GLAND CANCER CASE STUDY 
 
GENE PRIMER SEQUENCES LENGTH  
 Sense: AAGGCAGGGAGACCAGACT  
ATP5B* 89pb  Antisense:GCCTTCTGTACCATCCATAGCAATA  
Probe:AGCATTTGGGTGAGAGCACAGTA   
Sense: GTGTCATTAGTGAAACTGGAAAAGCA   HPRT* 91pb Antisense:CGATGTCAATAGGACTCCAGATGTT   Probe:CAAACTCAACTTGAACTCTC  
 Sense: CGCCAGCTCCTACGTGTT  
FTL-4 88pb  Antisense:CATGGCGTCCTTCCTGTT  
Probe:AGAGACTTTGAGCAGCCATTC   
Sense: GAAGCAGAGCCATGTGGT   VEGFR2 84pb Antisense:GTAGGAATCCACAGGAGAGA 
 Probe: CTGGTTGTGTATGTCCCACCCCAGA  
 Sense: TGCATGAACACCAGCACG  
VEGFC 85pb  Antisense:TTGTTACTGGTTTGGGGCCT  
Probe: GCTACCTCAGCAAGACGTTATT   
Sense: TGCCAGAAGCACAAGCTA   VEGFD 80pb Antisense: CTTGCACATGGTCTGGTATG  
 Probe: CAGACACCTGCAGCTGTGAGGACAG  
 
Table 11: primer/probe sequences and length of the amplicons used in the adrenal gland cancer case study. 
* HKGs chosen for expression data normalization 
 
First, the amplification conditions were empirically determined. These conditions were 
related to the amount of RNA and to the number of amplification cycles. Usually 
amplifications performed in nucleic acids from FFPE tissues require more PCR cycles in 
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comparison with fresh tissues because of the presence of inhibents and degraded starting 
material. In average the suggested number of cycles is 40-45.  
A linear relationship exists between the log of the quantity of RNA and the log of the 
specific amplified gene product being examined. This relationship is valid in a specific 
range, defined with the quantity of starting nucleic acid and the number of cycles of the 
PCR (Stanta et al., 1998c). These variables, known as linearity conditions, change with 
target genes, starting material (type of samples, fresh or FFPE tissues), but also with PCR 
primer sets. To search for the linearity conditions, first of all a constant amount of RNA 
(200ng) was amplified varying the cycles number from 30 to 50, with increment of 5 
cycles for each variation. The proper number of cycles was determined by the middle point 
in the calibration curve that plotted the log of PCR products vs the number of cycles. The 
second step to determine the linearity condition consisted in the repetion of the 
amplification with chosen number of cycles and with increasing quantities of RNA (50ng-
500ng). Again the optimal conditions were chosen for the quantity related to the middle 
point in the calibration curve. At this point, it was possible to analyse the whole case study 
using the previous chosen linearity conditions. The linearity conditions search were 
performed for both target and housekeeping genes.  
Tables 12 and 13 describe the optimal conditions in terms of starting amount of RNA and 
number of cycles for every tested gene in each case study. 
 
PCR CONDITIONS  HYBRIDIZATION CONDITIONS 
GENE 
T°a RNA for RT 
PCR 
cycles  T°hybr % form. 
ACTB 50°C 50ng 30  50°C 0.0 
AKT3 50°C 125ng 45  52°C 3.0 
BREAST CK8 50°C 500ng 50  46°C 0.0 CANCER CASE 
STUDY ERK1 50°C 30ng 35  52°C 3.0 
NM23 50°C 100ng 40  50°C 0.0 
PI3K 50°C 60ng 30  52°C 8.0 
p130 (RB2) 55°C 250ng 55  45°C 0.0 
RAF-1 55°C 120ng 40  52°C 4.2 
SEL-1L 51°C 15ng 45  45°C 0.0 
 
Table 12: Optimal amplification and hybridization conditions of genes in the breast cancer case study 
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PCR CONDITIONS  HYBRIDIZATION CONDITIONS 
GENE 
T°a RNA quantity 
PCR 
cycles  T°hybr % form. 
ATP5B 60°C 40ng 30  51.8°C 0.0 
 
 
 
 
ADRENAL 0.0 HPRT 50°C 60°C 20ng 35  GLAND CANCER 
FTL-4 55°C 80ng 35  46.5°C 0.0 CASE STUDY  0.0 VEGFR2 55°C 80ng 55°C 40   
0.0 VEGFC 58°C 50ng 50°C 45  
0.0 VEGFD 54°C 100ng 55°C 45  
Table 13: Optimal amplification and hybridization conditions of genes in the adrenal gland cancer case study 
 
The choice of the appropriate housekeeping genes was carried out preliminarly analysing 
in about ten cases (5 tumoral and 5 peri-tumoral if they were available) the expression of 5 
candidate housekeeping genes (found in the literature or already validated in previous 
studies) and selecting for the case study one to three of them that showed the lower 
expression variability among samples.  
For the breast cancer case study ACTB was chosen, while for adrenal gland tumor case 
study a combination of ATP5B and HPRT resulted the best choice.  
In practice, after DNase digestion followed by phenol/chloroform extraction, the optimized 
concentrations of RNA (see Tables 12-13) were reverse transcribed in a final volume of 
10μl using AMV-RT associated with the reverse specific primer.  
Solution contained AMV-RT buffer, 1mM dNTPs, 15pmol specific reverse primer, 2units 
AMV-RT, 4 units RNase inhibitor and total RNA to a final volume of 10μl. The reaction 
took place at 42°C for 60’.  
The whole reverse transcription product was used as a template for the PCR reaction.  
Amplification was performed in a final volume of 50μl by adding the PCR buffer (500 mM 
KCl, 100 mM Tris pH 8.3, without MgCl2), 15pmol specific forward primer and 2.5units 
Taq Polymerase. The solution was denatured for 3’ at 94°C, subjected to 5 cycles of 1’ at 
94°C, 1’ at the specific annealing temperature of the primer pair and 1’ at 72°C followed 
by a variable number of cycles of  30” at 94°C, 30” at the specific annealing temperature of 
the primer pair and 30” at 72°C. 
Detection of PCR products were carried out by radioactive-base dot blot hybridization 
(already described in 3.1.3), using the radiolabelled probes described in Table 11-12 in the 
optimized conditions (Tables 12-13) and the expression data normalization was then 
performed (against ACTB for breast cancer case study and against ATP5B and HPRT for 
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adrenal gland tumor case study) by submitting the raw quantification data (expressed as 
cpm) to the following formula:  
 Value norm= NF * value sample
 
Valuenorm is the normalized quantification value (expressed in cpm) of the target gene, NF 
is the ratio between the mathematical mean of the reference gene/panel of reference genes 
expression values in all the samples and the reference gene expression value referred to the 
investigated sample, Valuesample is the raw expression of the target gene. 
Normalized expression data were then submitted to the statistical analysis.  
 
5. STATISTICAL ANALYSIS  
Statistical analyses were performed with the package Stata/SE 9.0 (Stata Corp College 
Station, TX, USA). 
- In the optimization experiments basic statistics was used: mean, standard deviation, 
Pearson’s linear correlation.  
-  In the breast cancer case study T-test analysis was applied to compare the mean value of 
expression of each gene in the group of patients that had recurrencies to the mean value in 
the group that had not. To estimate the joint effects of the analysed covariates on patients’ 
survival, the data were analysed by fitting the Cox proportional hazards regression model 
as previously reported(Bonin et al., 2006). Cox proportional-hazards analysis included age 
at diagnosis, stage and grade of the tumours and the complete set of the molecular markers. 
In this analysis, tumors with expression of molecular markers lower or higher than the 
mean value were classified as low or high status of expression, respectively.  
To investigate possible associations among the genes detected by Cox regression analysis 
we chose pairs of molecular markers involved in opposite or conflicting functions. For 
these pairs of markers we considered groups defined by: high expression status of one 
marker and low expression status of the other one and the opposite situation. The chosen 
pairs of genes were: HER2 and Cytokeratin 8 as dedifferentiation/differentiation markers, 
CDK2 and RB as markers of cell cycle progression/senescence, PI3K and RAF1 as 
markers of the main branches of RAS pathways, PI3K and AKT3 as markers of cell 
proliferation. The Log-rank test was used to compare the survival between the above 
mentioned groups.  
- In the adrenal gland tumor case study the one-way ANOVA test combined with Sheffè 
testing was used to evaluate the differences in the expression levels of the four markers 
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(VEGFC, VEGFD, VEGFR2 and FLT-4) and of the microvessel density  in the four 
groups of the case study (peri-tumoral, adenomas, carcinomas, pheochromocytomas). 
Pearson’s correlation was used for the determination of the coupled relationships between 
the 4 tested genes in the 4 groups of the case study and between gene expression values 
and the MVD. 
Statistical difference was accepted at p value less than 0.05. p values between 0.06-0.07 
were considered “borderline”. 
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RESULTS 
 
As already reported in the “Aim of the study”, my research activity is related to possible 
clinical applications of molecular medicine. I divided my experience in the optimization of 
molecular kits for early diagnosis of transitional carcinoma tumors in urine and in the study 
of archive tissues to explore their use in molecular expression gene analysis. Especially 
this second part of my project is strictly connected with the European project “Archive 
tissues: improving molecular medicine research and clinical practice-IMPACTS” that is 
coordinated by our laboratory in Trieste. This fact explains my interest in the analysis and 
improvement of different molecular methods suitable for analysis in formalin-fixed and 
paraffin embedded tissues.  
 
1. TECHNICAL OPTIMIZATION OF MOLECULAR METHODS FOR GENE 
EXPRESSION ANALYSIS IN URINE 
Concerning the experience in molecular analysis of biological fluids and especially of 
urine, this part was focused on the optimization of some molecular procedures for gene 
expression analysis in urine samples, in order to improve their efficiency and accelerate  
the acquisition of the results in a diagnostic setting. To this porpose, the RNA extraction 
and the PCR product detection approach were analyzed.  
 
1.1 RNA extraction: five two-fold dilutions of T24 cells were used for a parallel RNA 
extraction with the conventional modified Chomczynski and Sacchi protocol 
(Chomczynski and Sacchi, 2006) and with a spin column-based experimental kit. This 
experimental kit does not use guanidinium thiocyanate or extraction/precipitation steps, but 
makes use of a spin column containing a diatomaceus earth that is cheaper and more 
suitable in the processing of urine samples. 
Each extraction was performed in triplicate. The concentration and purity results are 
reported in the following table (Table 1): 
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Table 1: comparison between classical and experimental kit RNA extraction according to RNA 
concentration and 260/280nm purity. Values are means of triplicate±standard deviations.  
 
The classical and the new method of RNA extraction presented similar results for higher 
RNA concentrations, while at lower concentrations our kit gave better results (it resulted 
six-fold more efficient than classical extraction using 2.5*105 cells and allowed a higher 
sensitivity with a RNA recovery even in the last dilution of 1.25*105 cells). 
These results are summarized in a graphical representation (Fig.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: sensitivity and efficiency of the two compared RNA extraction methods 
 
The purity results according to the 260/280nm ratio (that indicates the level of co-purified 
phenolic and protein contaminants) seemed to be very similar between the two methods 
but an increased RNA quality at lower concentrations was observed for the new extraction 
method (Table 1). 
CLASSICAL NEW KIT 
EXTRACTION EXTRACTION n° of 
cells Conc. 
μg/ul 
Conc. A260/280nm A260/280nm μg/ul 
62*10 1.04±0.05 1.86±0.04 1.06±0.05 1.7±0.03 
61*10 0.46±0.07 1.5±0.05 0.56±0.08 1.6±0.04 
55*10 0.09±0.25 1.4±0.05 0.28±0.08 1.65±0.04 
2.5*105 0.02±0.3 1.25±0.07 0.12±0.1 1.6±0.04 
1.25*105 - 0.0 0.06±0.2 1.55±0.05 
y = 0,5357x + 0,0008
R2 = 0,9983
y = 0,6046x - 0,1675
R2 = 0,9922
0
0,2
0,4
0,6
0,8
1
1,2
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1.2 PCR product detection: optimization of methods for gene expression analysis in urine 
samples involved essentially the signal detection approach. We used the radioactive signal 
detection as the reference method with which the colorimetric approach (ELOSA) was 
compared. This alternative approach could overcome the problems connected with the use 
of radioactive material that is not allowed in the majority of the clinical laboratories. 
Optimization of PCR product detection was performed on four genes (GAPDH, hTRT, 
CK20 and CD4) using both urine samples and cloned sequences as starting material. 
For each gene an optimization of the plate settings was performed. This included the 
definition of the most appropriate quantities of probe and PCR product in order to get a 
linear response.  
From 50 to 750 ng of each probe per well were tested; they were combined with 5 or 10μl 
of amplification product derived from 3 urine samples that showed different expression 
levels of the target genes. 
The signal was detected by a conventional ELISA reader and OD values for each sample 
were then reported in a graph from which the linearity conditions were obtained (Fig. 2). 
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Fig. 2: graphical representation of  OD values of the 4 genes according to the quantity of both PCR product 
(5-10μl) and probe (50ng, 100ng, 250ng, 500ng, 750ng). The vertical lines define the linear range determined 
experimentally for each gene. 
 
The limits of the dynamic range were defined in order to meet the linearity conditions of 
all the target genes. As reported in the four graphs of Fig.2, the concentrations of probes 
that give the best quantitative results are those between 100 and 250ng per well. If we look 
in this range it is possible to see that for GAPDH, hTRT and CK20 a better hybridization 
kinetic is connected on the average with the lower amplicon concentration (5μl). In these 
genes it seems that a higher concentration (10μl) of amplicon determines an inhibitory 
effect on signal detection. We could find a different behaviour for CD4, in which higher 
concentrations of amplicon (10μl) resulted to be the most efficient. In all the genes studied 
the OD signal increased up to 250ng of probe per well; higher quantities of probe did not 
improve the detection signal.  
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The following table summerizes the hybridization conditions that were finally chosen 
(Table 2): 
 
HYBRIDIZATION 
CONDITIONS  GENE 
ng probe ul amplicon 
 5μl GAPDH 100ng 
 
 
 
Table 2: optimal hybridization conditions in the ELOSA method. 
 
These optimized conditions were then checked with progressive dilutions (calculated in 
fmol) of previously amplified fragments for each of the four genes, for the definition of the 
linear quantitative range of detection. In this interval, it is present a linear relationship 
between the log of the quantity of the target sequence and the corresponding OD values. 
The dynamic range (OD dr) was defined as the range in which it was possible to fit a 
straight line across the points (Fig. 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: Dynamic range (OD dr) of  the signal detection using progressive dilutions of an amplified fragment 
corresponding to the 4 target genes. 
 
For every gene considered, the OD dynamic range corresponded, with minimal variations, 
to an interval between 5*102 and 4*103 fmol of amplified target. 
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Looking at the OD dynamic range (OD dr) reported in the graphs of Fig. 3, the 
hybridization kinetic was dependent on the gene. At the same target quantity,  GAPDH 
system gave the highest signal, followed by CD4, hTRT and CK20. For this reason a 
different OD dynamic range was determined for each gene (OD dr was between 1.1-3.1 for 
GAPDH, 0.5-1.7 for hTRT, 0.9-1.5 for CK20 and 1-2 for CD4). Only within this range it is 
possible to evaluate quantitative results with ELOSA method. 
Colorimetric quantification was then compared with the isotope-based (32P) internal probe 
hybridization dot blot. Twenty urine samples were analyzed, both by ELOSA colorimetric 
method and isotopic dot blot. The results were ordered according to the crescent signal 
intensity, as shown in the following graph (Fig. 4). 
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Fig. 4: graphical representation of  expression values (OD and cpm)  in ascendent order referred to 20 urine 
samples. 
 
The pattern observed with GAPDH, wa similar to the pattern observed for all the genes. 
Isotopic approach showed a wider linear range, the quantitative differences were detectable 
also at higher concentrations. ELOSA showed a plateau at higher values, but the sensitivity 
of the two methods were similar for lower concentrations. In both approaches, values that 
were beyond the linear range, were excluded from the quantitative analysis. 
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2. MOLECULAR METHODS FOR GENE EXPRESSION ANALYSIS IN 
ARCHIVAL TISSUES 
The major interest of our laboratory is to optimize reproducible methods for molecular 
analysis in archive tissues (in most of the cases formalin-fixed and paraffin-embedded 
tissues, FFPE). The goal of our European project, in fact, is to validate methods that can be 
then standardized and used for clinical analysis for prognostication and therapy prediction 
by the use of specific biomarkers. The first part of this study was focused on the 
optimization of some “home-made” molecular procedures for gene expression analysis in 
archival material. The second part was focused on the application of the methods on 
clinical case studies of breast cancer and adrenal gland tumors to detect quantitatively 
specific biomarkers at mRNA level.  
 
2.1 Technical optimization 
The technical optimization involved both the fixation step of tissues and the different 
phases of the molecular analysis, such as extraction, quantification, integrity assessment, 
cDNA synthesis and realtime amplification. In this part of my work, as already reported in 
“Material and methods” section, I compared in most of the cases standard procedures with 
new and alternative types of molecular approaches.  
2.1.1 Fixation: A375 cell line was used as based biological material to study different 
types of fixatives. This was done to obtain a reproducible and constant type of substrate for 
the analysis. Three fixatives were compared: conventional buffered formalin (NBF), a 
commercial fixative (FineFIX) and a home-made methacarnoy fixative.  
Although highly toxic, formalin still remains the most widely used fixative because it 
preserves a wide range of tissue components. However, formalin is a cross-linking agent 
that alters and fragments nucleic acids. 
FineFIX and methacarnoy fixatives are two alcohol-based solvents. Commercial FineFIX 
(Milestone) is a completely non toxic fixative and recently its preservative properties on 
macromolecules have been highlighed  (Stanta et al., 2006). Methacarnoy is an eccellent 
fixative for preserving tissue DNA, RNA and proteins, but is toxic (it contains methanol 
and chloroform).  
The three fixation procedures were analyzed after fixation for 1-3-6-12-24 hours. Total 
RNA was extracted with the modified proteinase K-based protocol. A non fixed aliquot of 
cells was used as positive control (C+) of quantity and quality of RNA. 
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Concentrations were assessed by a conventional spectrophotometer analysis at 260nm (Fig. 
5). 
For concentration values by type of fixative, we found that formalin fixation was the most 
aggressive on RNA recovery and even after 3 hours the yield was reduced to more than 
50% if compared to RNA from fresh cells.  
FineFIX fixation was the most conservative (RNA recovery was approximately 65% of 
that obtained from not treated cells even after 24 hours of fixation); methacarnoy fixation 
was approximately 50% less conservative than FineFIX treatment but it seemed to improve 
RNA recovery until the 12 hour-fixation. 
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Fig. 5: quantity of total RNA recovered from cells fixed with formalin, FineFIX and methacarnoy after 1, 3, 
6, 12 and 24 hours. 
 
Purity of the extracted RNA was defined by the 260/230nm (indicator of co-purified 
organic contaminants) and 260/280nm (indicator of phenol/protein contaminants) ratios 
and a mean value was calculated for each group (Table 3). 
 
 
 
 
 
 
 
 
 
 
 
Table 3: purity of total RNA at 230 and 280nm as measured by the spectrophotometer. C+ quantification 
was repeat in triplicate. 
 
The ratio at 260/230nm was lower for formalin-fixed samples (1.29), followed by 
methacarnoy (1.42) and FineFIX-fixed samples (1.74). As a good level of purity is 
Conventional spectrophotometer 
Fixative  260/230nm 260/280nm 
Formalin 1.29±0.4 1.61±0.14 
FineFIX 1.74±0.16 1.53±0.04 
Methacarnoy 1.42±0.2 1.53±0.02 
Fresh (C+) 1.91±0.01 1.47±0.02 
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considered from 1.8 and higher, we can see that only fresh cells and FineFIX treated cells 
were around this value.   
The ratio at 260/280nm was more constant between the different fixatives. As their value 
was lower that 1.8, this indicates the presence of co-purified contaminants (proteins, salts, 
phenol and other reagents). 
The degradation levels for all samples were assessed by a conventional electrophoretic gel. 
The run showed that formalin apparently preserved RNA better than the other two 
fixatives, as both the 28S and 18S bands were clearly evident in formalin fixation until 6 
hours of fixation. In alcoholic-based fixatives the ribosomal RNA appeared to be more 
degraded. In methacarnoy fixed cells only the 28S band was clearly evident (and it 
persisted along all the fixation times), while in FineFIX fixed cells only a smear is visible 
for most of the considered fixation times (Fig. 6). 
 
 
 
 
 
 
 
 
 
 
Fig. 6: Electrophoretic analysis of effects of fixation time on RNA quality induced by the three fixatives. 
Comparison was against RNA extracted from non fixed cells (C+).  
 
The effects of the type of fixative and the time of fixation were then assessed by a gene 
expression analysis of ACTB and ATP5B genes using a SybrGreen-based qRT-PCR. A 
standard quantitative curve in five dilutions starting from 40ng cDNA was prepared for 
each gene and for each treatment. For the comparative analysis, the Ct of the second 
dilution of each quantitative curve was used. 
Using the Ct value as representative of the level of gene expression, it was possible to 
show in formalin-fixed cells an evident correlation between the Ct values and the fixation 
times in both genes (Fig.7). A rapid increase in Ct values was found after 6 hours of 
fixation. The difference of Ct value between 1 hour formalin-fixed and fresh cells was 
about of  6.1 cycles for ACTB and of 7.6 for ATP5B. they increased rapidly with 
progressive fixation. 
FineFIX fixation Methacarnoy  fixation Formalin fixation 
28S 28S 28S 
18S 18S 18S 
5S 5S 5S 
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For ATP5B (which physiologically presents lower expression levels) the degradative 
effects did not allowed the detection of gene expression after 6 hours of fixation. 
In FineFIX and methacarnoy treated cells the RNA integrity was affected in the same way 
in comparison with fresh cells. The difference of Ct value between 1 hour-fixed and fresh 
cells was about of 4.4 cycles for ACTB and of 3.5 for ATP5B. The degradation level was 
constant for any fixation time.  
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Fig. 7: correlation  between Ct for ACTB and ATP5B and fixation times for the three fixatives; Ct are 
referred to the second dilution of each sample. 
 
For formalin fixation these results agree with those found by electrophoretic run, while   
completely contrasting results were found for FineFIX and methacarnoy fixation.  
A comparative gene expression analysis was also performed in order to assess how fixation 
procedure can alter the ratios between different mRNA species (Fig. 8). The ΔCt for 
ACTB and ATP5B were compared; their values were plotted in the following graph, 
according to the type of fixative and the fixation time. 
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Fig. 8: graphical representation of  ΔCt values between Ct values of ATP5B and ACTB according to the 
fixative and fixation time. 
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As represented in Fig. 8 we can see that different times of fixation can give evident 
differences in ΔCt values, if compared with the not fixed sample. For formalin fixation this 
difference increases sensitively with fixation time. For the other fixatives (FineFIX and 
methacarnoy) most of the variations are below 0.5 ΔCt values.  
 
2.1.2 RNA quantification: an accurate RNA quantification is important in order to reduce 
variability in terms of quantities used for the following DNase digestion and reverse 
transcription. Total RNA was extracted from cells fixed with different fixatives, using a 
protocol based on proteinase K digestion. A total of 16 samples was analyzed. RNA 
concentration was determined by three approaches: conventional spectrophotometric 
measurement, NanoDrop and Agilent Bioanalyzer (Fig. 9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9: correlations of concentration values obtained by spectrophotometric, Nanodrop and Bioanalyzer 
reading.  These results are referred to RNA extracted from fixed cells (see “2.2.1 Fixation” section of  this 
chapter) 
 
The higher quantitative correlation among methods was observed between 
spectrophotometer technique and Nanodrop (r = 0.98), mostly connected with the fact that 
both are spectrophotometric methods. Lower level of correlation was found between the 
Agilent Bioanalyzer and the two spectrophotometric procedures. 
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For Nanodrop measurement, purity of the extracted RNA was defined by the 260/230nm 
and 260/280nm ratios and a mean value was calculated for each group (Table 4a). 
 
 
Table 4: purity of total RNA as 260/230nm and 260/280nm ratios comparing Nanodrop (a) and conventional 
spectrophotometer (b) measurements. 
 
If compared with the spectrophotometric results (see 2.1.1), a good correlation between the 
two methods was found for the 260/230nm ratio; on the contrary, the 260/280nm ratios 
were higher for Nanodrop measurement. This was more evident for the non fixed sample 
(1.93 vs 1.47). 
 
2.1.3 RNA integrity assessment: the comparison between different approaches for RNA 
integrity assessment was performed to determine the most accurate method for a reliable 
prediction of mRNA accessibility for subsequent gene expression analysis. In this 
experiment the RNA integrity detection employed the same cell line system that was used 
for fixation evaluation (2.1.1). RNA from fresh cells was used again as positive control. In 
particular, the denaturing gel electrophoresis results, reported in the 2.1.1 section, were 
compared with those obtained with two alternative methods.  
The RNA integrity was first assessed using an Agilent 2100 Bioanalyzer. RNA 
degradation levels were evaluated by the analysis of the electropherogram, the “Ratio 
method” and the “RNA Integrity Number” (RIN). In Fig.10 the electropherograms for both 
fresh and fixed cells aree compared with the corresponding 28S/18S ribosomal ratios 
(“Ratio method”) and RIN value for each sample. For the intact positive control, the 
corresponding 5S, 18S and 28S peaks are also indicated. 
 
 
 
 
 
Conventional spectrophotometer 
Fixative 260/230nm 260/280nm 
Formalin 1.29±0.4 1.61±0.14 
FineFIX 1.74±0.16 1.53±0.04 
Methacarnoy 1.42±0.2 1.53±0.02 
Fresh (C+) 1.91±0.01 1.47±0.02 
Nanodrop b) a) 
Fixative 260/230nm 260/280nm 
Formalin 1.16±0.46 1.84±0.12 
FineFIX 1.61±0.23 1.95±0.02 
Methacarnoy 1.42±0.22 1.95±0.05 
Fresh (C+) 1.92±0.01 1.93±0.01 
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28S 
18S 
5S 
C+  
 
 
 
 
 
 
 
 Methacarnoy fixation Formalin fixation FineFIX fixation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10: electropherograms of the cells fixed with the three fixatives for different times.  RIN and rRNA 
ratios are also reported. Non fixed cells (C+) were used for the comparison. 
 
The electropherograms reproduced the pattern of electrophoretic results previously 
reported (see 2.1.1). In formalin fixation a rapid decrement with time of rRNA bands was 
followed by a progressive increase of low molecular weight fragments (5S). In FineFIX 
fixation  the rRNA peaks disappeared immediately after the first hour of fixation. In 
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methacarnoy fixation the persistence of the 28S peak was evident indipendently on the 
fixation time as already evidenced in the electrophoretic gel. 
No detectable correlations were found by 28S/18S ratio analysis.  
RIN values (good values for RNA integrity is major or equal to 6) depended on the 
fixative: in formalin fixation a progressive RIN decrease was noticed (from 9 to 2.6). This 
result was consistent with electropherogram assessment. For FineFIX fixation RIN values 
were constantly about 3 until 6 hours of fixation and then they were undetectable (this 
situation reproduces the pattern of the electropherogram assessment). For methacarnoy 
fixation the RIN values were not detectable in almost all the cases. 
Finally a smear analysis using the Agilent Bioanalyzer software was performed to assess 
RNA integrity. This was done by choosing ten intervals of RNA length (from 50 to 5000 
bases) analyzed by the Agilent Bioanalyzer, using the specific software. The results in the 
differently fixed cells are reported in Fig.11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11: smear analysis of RNA from cells fixed with the three fixatives for different times. The pattern of 
the not fixed cells is also reported in each graph. 
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Smear analysis stressed the percentage of fragments that were available in each interval of 
length after fixation. 
After 3 hours of  formalin fixation 50% of the fragments were still present between 2000 
and 6000 bases, but after 6 hours 70-80% of the fragments were between 100 and 300 
bases. With FineFIX fixation the degradation seemed to be constant for the different times, 
40% of the fragments were between 100 and 300 and 40% between 500 and 3000 bases. 
With methacarnoy fixation a persistence of high molecular weights fragments 
(corresponding to 28S rRNA) was seen even after 24 hours of fixation: in this time 40-60% 
of the fragments were still between 3000 and 5000 bases; during fixation however, a 
progressive increment of the 5S peak was also shown. 
Integrity assessment on both fresh (C+) and fixed cells was finally performed by end-point 
reverse transcription using the MMVL-based protocol and amplification of 5 beta-actin 
fragments in a range between 77 and 651 bp. Results were visualized in an acrylamide gel 
stained with ethidium bromide (Fig.12). 
 
77 base pair  
 
 
 
 
 
 
 
 
METHACARNOY 
77 bp - 
  1h       3h      6h    12h    24h       C+       C- 
FORMALIN FINEFIX 
77 bp - 
   1h       3h       6h    12h    24h    1h       3h      6h    12h    24h 
177 base pair 
 
METHACARNOY 
177 bp - 
  1h       3h      6h     12h    24h      C+       C- 
 
 
 
    1h        3h       6h     12h      24h        
FORMALIN FINEFIX 
177 bp - 
1h        3h      6h     12h     24h        
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291 base pair 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12: Electrophoretic results on a 8% acrylamide gel of RT-PCR products from  beta-actin fragments of 
increasing length (between 77 and 651 bases) 
 
Considering the different fixation times for each fixative, successful amplification for 
formalin produced fragments no longer than 170bp and even for short fragments a 
progressive degradation of RNA was evident: after 12 hours of fixation no amplification 
was detectable.  
Methacarnoy and FineFIX gave similar results: amplification was successful for all the 
considered samples until 438bp with no apparent differences in amplification efficiency 
438 base pair 
651 base pair 
FORMALIN FINEFIX 
291bp - 
   1h       3h      6h     12h    24h      1h       3h       6h    12h    24h        
291bp - 
METHACARNOY 
  1h        3h         6h         12h        24h        C+          C- 
438bp - 
FORMALIN FINEFIX 
   1h       3h       6h      12h     24h          1h      3h      6h       12h     24h       
438bp - 
METHACARNOY 
  1h        3h         6h        12h       24h       C+        C- 
651bp - 
METHACARNOY 
  1h        3h         6h      12h        24h       C+        C- 
651bp - 
FORMALIN FINEFIX 
    1h       3h       6h      12h      24h           1h        3h       6h      12h     24h        
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between 1 and 24 hours of fixation. The amplification of the longest fragment (651bp) was 
still detectable but not in all samples and it was not correlated with fixation time. 
The results obtained with the RT-PCR seemed to correlate with those obtained with 
electrophoretic run and Agilent methods for formalin treated cells.  
However, when RT-PCR results were compared with electrophoretic run, 
electropherogram, rRNA ratio and RIN, contrasting results were seen for FineFIX fixation 
during prolonged fixation. None of these methods could in fact predict the successful RT-
PCR results that were obtained even for longer fragments. For methacarnoy fixation the 
identification of 28S peak by electropherogram assessment could someway explain the 
good amplification results. 
The results obtained with the RT-PCR seemed to correlate best with the smear analysis 
supplied by Agilent Bioanalyzer. For all the fixed samples, in fact, the distribution of the 
fragment ranges reproduced the pattern of the RT-PCR results. 
The results by endpoint PCR agree with the previously reported analysis by the realtime 
PCR (see 2.1.1), that confirmed that FineFIX and methacarnoy fixation preserves mRNA 
from degradation and leaves it accessible for subsequent amplification. 
 
2.1.4  DNase treatment: in all the protocols analyzing RNA from tissues it is suggested to 
eliminate DNA contamination using a DNase treatment. This is because the presence of 
pseudogenes can give aspecific results. Otimization of this protocol was performed using 
six different formalin fixed and paraffin embedded breast cancer samples. After 
deparaffinization and total RNA extraction by the proteinase K-based protocol, the samples 
were submitted to two parallel DNase treatments. In the first one the DNase digestion was 
followed by heat inactivation, in the second one DNase digestion was followed by  
phenol/chloroform extraction. RNA quantification was repeated only in the latter case. The 
effects of these two approaches were tested by a realtime-based gene expression analysis 
on ACTB gene. A standard quantification curve was prepared for each sample and the 
mean value of sensitivity (defined as a mean of the second dilution Ct values of the six 
samples), coefficient of determination (R2) and PCR efficiency (E) were used for the 
comparison (Table 5). This step was performed to determine if the presence of the 
denaturated enzyme and the other components could affect the procedure of amplification. 
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ACTB gene expression analysis 
DNase + 
PHENOL/CHLOROF.EXTRACTION 
DNase + HEAT 
INACTIVATION  
Sensit. 
(mean Ct) R
2 E  Sensit. (mean Ct) R
2 E 
23.5±2.3 98,8%±0,5 95%±3,3  24,6±2,4 99,2%±0,5 96%±4,2 
 
Table 5: comparison between the two DNase treatments, according to sensitivity, correlation and efficiency 
(E) of the PCR reaction using RNA from six FFPEs 
 
No significant differences were found between the two approaches in terms of correlation 
and efficiency. A higher sensitivity was found for DNase treatment followed by 
phenol/chloroform extraction (ΔCt = 1.1 approximately); this could be also due to slight 
differences in the upstream RNA quantification and to the high inter-sample variability.  
 
2.1.5  Reverse transcription: one of the most variable steps in RT-PCR analysis is the 
reverse transcription step, that may vary depending on the priming strategy and the 
enzymes. The performance of cDNA synthesis step was analyzed by comparing strategies 
that differed essentially for the enzyme and priming strategy used. An RNA pool deriving 
from colon cancer formalin fixed and paraffin embedded sections was employed. In detail, 
different combinations of reverse transcriptase enzymes (MMLV or AMV) and priming 
strategy (random hexamers, random 15-mers and a mix of specific reverse primers) were 
used. The combination of MMLV enzyme with random hexamers at low concentration was 
considered our reference procedure (Godfrey et al., 2000). The “multiplex” reverse 
transcription consisted of  a mixture of all the specific reverse primers (12pmol/each per 
reaction) in the same reverse transcription solution. All the reverse transcriptions were run 
in triplicate. For this optimization experiment TS, TP and DPD genes were used, in 
addition to ACTB.  
The effects of the different strategies were tested by a SybrGreen realtime-based gene 
expression analysis on ACTB, TS, TP and DPD genes. For realtime PCR a fixed quantity 
of cDNA (40ng) was used for sensitivity and standard deviation determination, and these 
values were used for the definition of the first three more reliable strategies. Then, a 
standard curve was prepared for each sample and the values of coefficients of 
determination (R2) and PCR efficiency (E) were used for the final comparison. 
Results of sensitivity and reproducibility (SD) of the triplicates showed that the best 
reverse transcription combination for all the tested genes was that of AMV enzyme 
associated with the mix of specific reverse primers (considering the three genes together, a 
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mean difference of 7.3 Cts was found between this combination and that formed by 
MMLV plus random hexamers at low concentration). The second and third more sensitive 
strategies were those of MMLV enzyme combined with both 6-mers and random 15-mers 
at high concentrations: a mean difference of 0.18 Ct was found between them. A mean 
difference of 3.6 Cts was shown between MMLV plus random primers at high 
concentrations and AMV plus the mix of specific reverse primers (Table 6). 
 
GENE 
 
Table 6: Sensitivity and standard deviations (SD) of realtime amplifications using different combinations of 
reverse transcriptases and priming strategy. A pool of RNA from colon cancer specimens was used. 
Sensitivity was referred to the Ct obtained from 40ng cDNA; SD was determined by comparing the 
triplicates of the RT). In bold font the most sensitive combinations are indicated.  
 
When efficiencies (E) and coefficients of determination (R2) were studied for these three 
combinations (MMLV plus both 6-mers and random 15-mers at high concentrations, and 
AMV plus the mix of specific reverse primers), it was found that the best method resulted 
the combination of MMLV with random 6-mers, followed immediately by MMLV with 
random 15-mers (Table 7). On the contrary, AMV gave for all the target genes the lower 
efficiency and correlation values (for example the efficiency for DPD was 32%).  
 
 
 
 
ACTB TS TP DPD PRIMING 
STRATEGY 
Primer conc. ENZYME (mol/reaction) Sensit. 
(Ct) 
SD Sensit. SD Sensit. SD Sensit. SD 
(Ct) (Ct) (Ct) 
0.167nmol 25.03 0.24 36.54 1.4 31.77 0.21 35.08 0.5 
6-mers 
21.66 32.38 29.33 31.86 3.35nmol 0.17 0.30 0.11 0.21 
0.167nmol 24.22 0.22 34.37 0.18 31.37 0.18 33.16 0.35 
MMLV 
(250units) 
15-mers 
21.5 31.27 29.57 31.72 3.35nmol 0.29 0.38 0.28 0.36 
- - - - - - - - - 
6-mers 
3.35nmol 27.83 0.18 38.39 0.26 34.07 0.1 37.2 0.25 
- - - - - - - - - AMV 
15-mers 
3.35nmol 29.31 1.36 38.02 0.68 35.76 1.24 36.49 0.26 
(4units) 
Mix of 20.12 29.49 26.83 24.89 12pmol each 0.17 0.27 0.009 0.19 primers 
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GENE 
 
Table 7: Efficiencies (E) and correlations (R2) determined for  the three more efficient RT approaches. In 
bold font the most efficient combination is indicated. 
 
2.1.6  Quantitative realtime PCR: quantification of the amplification results is one of the 
most cumbersome problems in the application of PCR to the clinical practice. SybrGreen 
and TaqMan chemistries were indipendently validated in realtime PCR using the same 
primer sequences; the optimized conditions were first used to compare performances in 
plasmid-cloned sequences. Seven 1:10 scalar dilutions starting from 107 and 108 copies of 
cloned sequences for ATP5B and HPRT, respectively, were used and two standard curves 
were prepared for each chemistry (Fig.13). Values of coefficient of determination (R2), 
efficiency (E) and dynamic range were used for the comparison between the two realtime 
approaches. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Fig. 13: graphical representation and the corresponding summary table of R2, efficiencies (E) and dynamic 
range for ATP5B and HPRT determined on cloned sequences using the optimal amplification conditions. 
Dynamic range was referred to the interval both of Ct values and target copy number. 
 
ACTB TS TP DPD 
Primer PRIMING ENZYME STRAT. conc. 
E R2 E R2 E R2 E R2
6-mers 100% 100% 100% 3.35nmol 0.979 0.991 98% 0.996 0.996 MMLV 
(250units) 100% 15-mers 100% 3.35nmol 0.987 85% 0.974 0.989 89% 0.976 
AMV Mix of 12pmol 85% 0.995 91% 0.963 80% 0.992 80% 0.905 (4units) primers 
log HPRTcopies
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log ATP5B copies
C
t
ATP5B 
TaqMan vs SybrGreen
y = -3,6058x + 41,165
R2 = 0,9991
y = -3,4141x + 43,518
R2 = 0,9953
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log copie HPRT
C
t
HPRT 
SybrGreen
TaqMan
SybrGreen
TaqMan
 SybrGreen TaqMan 
GENE R2 E Dynamic range   
Dynamic R2 E range 
17.5-34.9 17.8-34.6 
ATP5B 0,995 98%  0,999 97% (107-102) (107-102) 
13.5-30.9 16.4-33.8 
HPRT 0,995 98%  0,998 95% (108-103) (108-103) 
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The performance of the two systems depended on the target gene. In ATP5B expression 
analysis SybrGreen and TaqMan approaches gave consistent results, while for HPRT they 
showed a significant difference in sensitivity (in SybrGreen chemistry the Ct value of the 
fist dilution, corresponding to 107 molecules, resulted approximately 3Ct lower than the 
corrisponding dilution in TaqMan chemistry). 
The comparison between the two approaches was then performed on RNA extracted from 
six adrenal gland FFPE samples. For each sample serial 1:5 dilutions were prepared 
starting from 40ng of cDNA and a standard curve was run for each gene using both 
SybrGreen and TaqMan chemistry. 
Their performance was assessed considering the mean value of the sensitivity, expressed as 
the Ct value of the first dilution, the coefficient of determination (R2), the PCR efficiency 
and the dynamic range of the reaction.  
The results on FFPEs showed a difference in the sensitivity between the two chemistries 
and this difference was related to the target gene (Table 8). For ATP5B the difference of Ct 
value was lower than 1 (ΔCt=0.7, in this case TaqMan chemistry was more sensitive), for 
HPRT this difference was more consistent (ΔCt=2.3, in this case SybrGreen chemistry was 
more sensitive). For both genes, the quantitative dynamic range resulted more limited for 
SybrGreen than for TaqMan chemistry (approximately 2 Ct values).  
 
SybrGreen  TaqMan  
 
Table 8: comparison between TaqMan and SybrGreen chemistry, according to their sensitiviy, R2, PCR 
efficiency (E) and dynamic range.  
 
 
2.2 Application of molecular methods to gene expression analysis in two archival case 
studies 
In this part of the study the clinical application of  molecular methods was performed for 
gene expression analysis in two archival case studies. 
The breast cancer case study was collected to investigate possible prognostic biomarkers; 
the adrenal gland cancer case study was analyzed to detect possible biomarkers for 
molecular characterization. 
GENE Sensit. (Mean Ct)    R
2 E 
Sensit. Dynamic Dynamic 
range (Ct)     R
2 E range (Ct)  (Mean Ct) 
ATP5B 25,6±2,61 0,991 89% 25,6-33,5  24,9±2,54 0,989 91% 24,9-35,4 
HPRT 26,5±1,76 0,99 95% 26,5-32,3  28,8±1,69 0,99 92% 28,8-34,5 
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In both cases a quantitative end-point analysis was used instead of a realtime PCR to lower 
the costs of the research and to continue a long experience of our laboratory in this type of 
investigation that gives similar quantitative results.  
 
2.2.1  Breast cancer case study 
A cohort of 80 women affected by infiltrating ductal carcinoma of the breast with long 
follow-up periods was considered. The axillary lymph nodes were tumour-negative in 43 
patients, while they were positive in 37 patients at the time of diagnosis of the primary 
tumor During the period of observation, 42 patients developed distant metastases. 
By using quantitative “end-point” RT-PCR, it was looked at the mRNA expression level of 
22 genes belonging to RAS pathway (EGFr1 and 2, k-RAS, RAF-1, ERK1, PI3K, AKT3), 
to cell cycle regulation/senescence (Cyclin A, D1 and E1, CDK2, CDK4, CDK6, p16, 
RB2, RB, CDC25a), to telomerase complex [(mRNA coding for catalytic component 
(hTRT) and RNA component (hTR)] and differentiation/metastasis suppression genes such 
as NM23, SEL-1L and CK8. Genes were selected according to their known links to 
malignant cell behaviour in breast cancer and their importance in major cancer hallmarks, 
such as cell senescence/proliferation and survival. 
Total RNA was extracted using the conventional protein K-based protocol (see 4.1.1.2 of 
“Materials and methods” section). Then, total RNA was converted to cDNA using the 
AMV-based protocol (see 4.2 of “Materials and methods” section), using one preparation 
for each considered gene, and amplification was performed using a semi-quantitative 
conventional RT-PCR assay. ACTB was used as normalization factor. PCR products were 
detected by radioactive-based hybridization assay and normalized data were statistically 
interpreted. The level of expression was defined as high or low according if it was higher 
or lower of the mean value. 
The following results have been recently published (Bonin et al., 2008). 
This study confirms our previous findings on CDC25A (p=0.01), CDK2 (p=0.01) and 
CDK4 (p=0.03) higher expression in the groups of patients who developed recurrences in 
comparison with patients that did not(Bonin et al., 2006).  
From the results of the Cox proportional hazard regression analysis, an independent 
influence on cancer specific death was detected for AKT3 (p= 0.01), RAF-1 (p= 0.05) 
CDK2 (p= 0.04), cytokeratin 8 (p= 0.04), Retinoblastoma (p= 0.03) and HER2 (p= 0.02) 
was shown. A borderline influence on patients’ survival was detected for PI3K (p= 0.06). 
Conversely, tumour stage and grade, patients’ age at diagnosis and the remaining 
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molecular markers analysed did not show an effect on survival. After dividing the stage 
into lymph node status (positive or negative for metastasis) and tumor dimension (diameter 
expressed in centimetres) the results of Cox proportional hazard regression analysis were 
restated. In this case study, lymph node status and tumor diameter did not affect patients’ 
survival (p= 0.1 and p= 0.5 respectively).  
Among the genes related to survival, AKT3, CK8 and RB seem to have a protective effect.  
Higher expression levels were indeed associated with better prognosis (Fig.14).  
 
 
 
a) b) 
 
 
 
 
 
 
c) 
 
 
 
 
 
 
 
Fig. 14: Survival curves related to Cox proportional hazard regression with respect to:  a) AKT3 expression 
level in the subgroups of low AKT3 or high AKT3; b) CK8 expression level in the subgroups of low CK8  or 
high CK8; c) RB expression level in the subgroups of low RB or high RB.  
 
Conversely, CDK2, HER2, PI3K and RAF-1 showed a worse effect on patient survival 
(Fig.15).  
 b) 
 
a) 
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c) 
 
 
 
 
 
 
d) 
Fig. 15: Survival curves related to Cox proportional hazard regression with respect to: a) CDK2 expression 
level in the subgroups of low CDK2  or high CDK2; b) HER2 expression level in the subgroups of low 
HER2 or high HER2; c) PI3K expression level in the subgroups of low PI3K  or high PI3K; d) RAF-1 
expression level in the subgroups of low RAF-1 or high RAF-1  
 
Moreover, groups of patients with high expression status of RB, but low expression status 
of CDK2 showed a longer disease-free survival in comparison to the group characterised 
by low RB status and high CDK2 status (p= 0.001) as described in Figure16a. A border-
line significance (p= 0.07) was detected when pairing cytokeratin 8 and HER2 status 
(Figure 16b). The associations RAF1-PI3K and PI3K-AKT3 as well as the pairing between 
RAF1 and AKT3 did not show to be related to patients’ survival (p= 0.9 and p= 0.7 
respectively).  
 
 
 
 
 
 
 
 
a) b) 
Fig. 16: Kaplan-Meier survival curves for patients with respect to RB and CDK2 expression level in the 
subgroups of high RB and low CDK2 or low RB and high CDK2 status (a) and CK8 and HER2 expression 
level in the subgroups of high CK8 and low HER2 or low CK8 and high HER2 status (b).  
 
Seventy-three percent of patients belonging to the group with low RB and high CDK2 
status died during the first 5 years of follow-up. A similar pattern was found for the group 
described by low CK8 and high HER2, in which 47% of patients died within the 5th year of 
follow-up. Moreover, the groups described by these two couples did not share any patients. 
Conversely, breast cancer patients described by high RB and low CDK2 showed a 5 and a 
 67
Results 
10 year survival of 77% and 68%, respectively. Similarly, the survival of patients with 
high CK8 and low HER2 was 81% and 69% at 5 and 10 years, respectively. These two 
groups overlapped for 3 patients. The 4 groups identified by these couples of markers 
included 45 of the 80 patients (56%). 
 
2.2.2  Adrenal gland tumor case study 
The role of angiogenesis was investigated in a small case study of adrenal gland tumors. 
To elucidate the isolate and combined role of VEGFR2 and FLT-4 (cell surface receptors 
of angiogenesis and lymphangiogenesis respectively), and their ligands, VEGFC and 
VEGFD in different types of adrenal gland tumors, paraffin embedded sections from 15 
adenomas, 9 carcinomas, 10 benign pheochromocytomas (total of 34 cases) were collected. 
For 5 tumoral specimens (1 carcinoma, 3 pheochromocytomas and 1 adenoma) 
microdissection was necessary and the peritumoral component was also considered. A 
gene expression analysis on these four genes was performed at mRNA level and the results 
were compared to immunohistochemical investigations using CD31 antibody (normally 
used for the vascular microvessel density count). 
The case study was then divided in 4 main groups, consisting of the following specimens: 
15 adenomas, 9 carcinomas, 10 pheochromocytomas and 5 peri-tumoral tissues. 
Expression analysis was performed by taking into account the histological classification. 
Total RNA was extracted using the conventional protein K-based protocol. 
In a preliminary study for HKG validation we found that in our specific experimental 
conditions ATP5B and HPRT were the most stable genes and they were included in the 
relative gene expression analysis as reference genes for data normalization. 
Total RNA was converted to cDNA using AMV and specific reverse primer, and 
amplification for the 2 HKGs and the 4 markers was performed using a semi-quantitative 
endpoint RT-PCR assay. PCR products were detected by radioactive-based hybridization 
dot blot and normalized data, expressed as cpm values, were statistically interpreted.  
 
Quantitative analysis of the 4 target genes in the three tumoral groups: 
Mean, range and median for each normalized target genes are reported in the following 
table (Table 9): 
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NORMALIZED FLT-4 mRNA 
EXPRESSION (cpm) 
 NORMALIZED VEGFR2 
mRNA EXPRESSION (cpm) TYPE OF 
TUMOR CASES 
Mean Range Median  Mean Range Median 
Peri-tumoral 5 8.51±4.4 6.1-13.2 8.1  7.35±4.6 8.23-18.5 11.6 
Adenoma 15 12.47±5.96 2.06-24.9 11.94  16.1±6.17 7.49-27.4 15.11 
Carcinoma 9 6.3±5.17 1.25-16.9 4.63  8.52±5.72 3.63-22.6 7.26 
Pheochrom. 10 6.21±4.6 0.08-17.2 6.19  12.1±6.47 3.58-27.7 10.79 
 
NORMALIZED VEGFC mRNA 
EXPRESSION (cpm) 
 NORMALIZED VEGFD mRNA 
EXPRESSION (cpm) TYPE OF 
TUMOR CASES 
Mean Range Median  Mean Range Median 
Peri-tumoral 5 4.25±1.82 3.06-7.32 3.19 8.47±4.63 4.63-16.47 6.61 
Adenoma 15 8.19±6.14 1.04-18 6.5 
 
6.27±3.77 0.39-14.2 5.17 
Carcinoma 9 5.04±6.78 0-20.36 2.24  2.97±2.69 0.57-7.85 1.96 
Pheochrom. 10 2.97±2.53 0.65-9.62 2.33  2.94±2.7 0.13-7.76 1.81 
 
Table 9: mean, range and median values for each normalized target gene expression according to the three 
tumoral groups and in the peri-tumoral component. 
 
FLT-4 expression was significantly different between adenomas and pheochromocytomas 
(p=0.045), and borderline between carcinomas and adenomas (p=0.06) (Fig.17). 
VEGFR2 showed statistically significant differences in the expression levels between the 
groups of adenomas and carcinomas (p=0.04).  
VEGFC did not show significant differences in the expression levels in the 4groups. 
Statistically significant differences in expression levels of VEGFD were detected between 
peri-tumoral samples and pheochromocytomas (p=0.049), while “borderline” differences 
were shown between peri-tumoral samples and carcinomas (p=0.056). 
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Fig. 17: graphical representation and p values associated with the differential expression levels of FLT-
4,VEGFR2, VEGFC and VEGFD in the three tumoral groups and the peri-tumoral component. In bold the 
significant p values are indicated. 
 
 
Correlations between the 4 markers in the 4 groups of the case study: 
The correlation between the 4 angiogenetic factors was analysed separately in the 3 
tumoral groups and in the peri-tumoral component. 
Correlation coefficient values (r) were obtained by comparing couples of normalized 
expression levels of the 4 target genes, expressed as cpm (Table 10). 
Considering the peri-tumoral component, direct correlations were found between VEGFR2 
with both the ligands (r=+0.63 and r=0.71 between VEGFR2 and VEGFC and VEGFD, 
respectively), while inverse correlations were found between FLT-4 and the other genes 
(r=-0.72, r=-0.62 and r=-0.59 between FLT-4 and VEGFR2, VEGFC and VEGFD 
respectively). However, p value resulted not significant due to the low number of 
CA    p=0.04   
Peritum. p=0.45 p=0.81  p=0.35 p=0.46   p=0.045 PHEOCHR. p=0.92 p=0.61 p=0.45 p=0.629 p=0.55 
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Peritum. p=0.31 p=0.28  p=0.48 p=0.056   PHEOCHR. p=0.136 p=0.865 p=0.56 p=0.57 p=0.38 p=0.049 
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considered samples. Conversely, the correlation between VEGFC and VEGFD resulted 
very high (r=0.91) and statistically significant (p=0.02).  
In adrenal cortex adenoma, correlations of VEGFD with other genes were lost but a 
discrete positive correlations was maintained between the two receptors (r=+0.68) and 
between VEGFC and the receptors (r=0.58 and r=0.52 with FLT-4 and VEGFR2 
respectively). 
In adrenal cortex carcinoma, a strong positive correlation between the two receptors was 
still present (r=0.92) but VEGFC correlations were lost. Strong positive correlations were 
found between VEGFD and the two receptors (r=0.85 and r=0.76 with FLT-4 and 
VEGFR2 respectively). 
In medullary pheochromocytoma, a strong correlation was found between the two 
receptors (r=+0.93). 
 
 
 
 
Table 10: Pearson’s correlations, expressed as r value, among the normalized gene expression of the tested 
genes in each group of the case study. In bold the significant correlations are indicated. 
 
A summarizing graphical representation was supposed on the basis of the significant 
correlations that were found among the four genes in the 4 groups (Fig.18). 
 
 
 
 
ADENOMA 
 
VEGFR2 VEGFC VEGFD 
FLT-4 +0.68 p=0.005 
+0.58 
p=0.021 
+0.18 
p=0.505 
VEGFR2  +0.55 p=0.03 
-0.189 
p=0.5 
VEGFC   +0.31 p=0.24 
PERI-TUMORAL TISSUE 
 
VEGFR2 VEGFC VEGFD 
-0.72 -0.62 -0.59 FLT-4 p=0.17 p=0.27 p=0.29 
+0.63 +0.71  VEGFR2 p=0.25 p=0.18 
+0.91 VEGFC   p=0.02 
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VEGFR2 VEGFC VEGFD 
FLT-4 +0.93 p<0.001 
+0.23 
p=0.52 
+0.18 
p=0.62 
VEGFR2  +0.28 p=0.43 
-0.03 
p=0.93 
VEGFC 
  -0.21 
p=0.55 
CARCINOMA 
 
VEGFR2 VEGFC VEGFD 
+0.92 +0.85 -0.03 FLT-4 p<0.001 p=0.0038 p=0.94 
VEGFR2  -0.06 +0.76 p=0.02 p=0.88 
  -0.1 
VEGFC p=0.78 
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Fig. 18: schematic representation of the gene expression correlations among the four target genes in the four 
groups. 
Red lines and (-) correspond to an inverse correlation; black arrows and (+) correspond to a positive 
correlation 
 
Correlations between MVD and angiogenetic/lymphangiogenetic factors: 
Angiogenesis was quantified by visual microvessel density count, using CD31 antibody as 
a marker for vascular endothelium (Fig.19). 
Microvessel density for each sample was determined as the mean number of microvessels 
recorded in three “hot spots” at 250x power field.  
 
 
 
 
 
 
 
 
 
Fig. 19: Example of CD31 protein staining of two pheochromocytomas with low (a) and high (b) 
microvessel density (250x power field) 
 
a) b) 
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The following table summerizes the mean value, range and median of the MVD results for 
each group (Table 11). MVD was expressed as the mean value of the microvessel count in 
the three most vascularized areas of each sample. 
Number 
of cases GROUP Mean Range Median 
Adenoma 15 77±55 30-214 58 
Carcinoma 9 120±96 25-363 88 
Pheochrom. 10 142±74 49-248 130 
Peri-tumoral 5 55±41 11-105 57 
 
Table 11: Mean, range and median of microvessel density values found in each group of the case study. 
 
 
Correlation coefficient values (r) were obtained by comparing the normalized expression 
levels of the 4 target genes with MVD values of each group (Table 12). 
 
 MVD  
 GENE PERI-TUMORAL ADENOMA CARCINOMA PHEOCHROM. 
 +0.88 +0.23 +0.01 +0.469 FLT-4 p=0.034 p=0.46 p=0.85 p=0.15 
 +0.93 -0.01 -0.219 -0.38 VEGFR2 p=0.005 p=0.75 p=0.68 p=0.24  +0.12 +0.356 +0.15 -0.097 VEGFC p=0.66 p=0.26 p=0.5 p=0.8  
+0.79 +0.28 +0.15 -0.216  VEGFD p=0.02 p=0.46 p=0.56 p=0.65  
 
Table 12: Pearson’s correlations between MVD and the four tested genes in each group of the case study. In 
bold the significant correlations are indicated. 
 
Strong correlations between microvessel density and both the two receptors and VEGFD 
were found in the group of carcinoma samples. 
No significant associations between angiogenesis and mRNA expression levels of the 
tested genes were found in the other groups. 
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DISCUSSION 
 
1. CHALLENGES OF MOLECULAR MEDICINE 
The “one drug fits all” paradigm of drug discovery has been the standard for many years, 
but in the last decades medicine is shifting towards “the right drug at the right dose in the 
right patient”, also known as personalized medicine. The optimism towards a concrete 
development of this field has been promoted by advancements in molecular methodologies 
that offer the opportunity to assess genetic alterations comprehensively and rapidly in 
routinely acquired samples. This will enable pathologists to use them as part of the routine 
process of cancer diagnostics adding the predictive information that conventional histo-
morphological diagnosis cannot reveal for successful targeted cancer therapy. 
The recent advances in molecular pathology enabled discovery of hundreds of candidate 
biomarkers with potential clinical value before cancer diagnosis (in risk assessment and 
screening), at diagnosis, and after diagnosis (in monitoring therapy, selecting therapy and 
detecting recurrences). Paradoxically, however, a concomitant progressive decrease in 
biomarker approval has been shown (Fig.1). This was recently noticed especially for 
plasma proteins (Anderson and Anderson, 2002).  
 
 
 
 
 
 
 
Fig. 1: Numbers of publications on biomarkers and FDA approval of biomarkers. 
Triangles and the associated trend line (green) represent the number of FDA-approved plasma-protein 
markers per year. Red squares and circles indicate publications under the Medline medical subject heading 
'biomarker' and text word 'biomarker', respectively. (Ludwig and Weinstein, 2005). 
 
 
Furthermore, almost none of the few FDA-approved biomarkers are used in standard 
clinical practice, and only two of them have made it into the TNM staging guidelines 
(HER2 (Wolff et al., 2007) and ER (Anderson et al., 2002)). None of them were 
discovered through the new high-throughput genomic or proteomic technologies. 
An acceleration in the development of useful biomarkers is possible if an integration of 
molecular and clinical data is fully realized: human biospecimens and the correlated 
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clinical data represent in fact the ideal source for biomarker discovery as they complete the 
molecular information derived from the laboratory research. 
As it has been highlighted by FDA (Food and Drug Administration) and IMI (Innovative 
Medicine Initiative), the major obstacles in this bidirectional flow of information are 
represented by insufficient expertise in the translation of molecular methods to clinical 
practice and by the high heterogeneity of human specimens that are collected for molecular 
studies. 
This scarce experience involves not only the emerging molecular technologies but affects 
also the more conventional approaches, that lack in sufficient standardization and 
optimization level for a reliable use in clinical practice. 
Thanks to the possibility to have access to the fresh and archival samples from the hospital, 
our laboratory can investigate these technical problems directly on clinical material, and 
exploit them in several molecular analysis on clinical case studies. 
The work of my thesis is strictly correlated to this activity. In particular, most of my PhD 
thesis developed in the context of a European project called “Archive tissues: improving 
molecular medicine research and clinical practice-IMPACTS”. This project represents the 
collaboration of many researchers within our laboratory and in the other 20 centres spread 
in 11 European countries. Most of my work must be combined with that of many other 
researchers that developed other aspects of the project, and this gives reason for the 
different experiences that I acquired in this multilaboratory project. This work involved a 
technical optimization step followed by their clinical application for candidate biomaker 
discovery directly in human case studies. 
Another part of my PhD thesis was focused on the technical optimization of molecular 
methods for expression analysis in biological fluids and especially in urine samples.  
All the optimization steps were performed through the direct comparison in clinical 
material of protocols validated in our laboratory or normally reported in literature with 
alternative procedures (that are already used in literature but need validation in biological 
specimens, or represent a technological innovation for molecular studies). 
 
2. MOLECULAR METHODS FOR GENE EXPRESSION ANALYSIS IN URINE 
Our laboratory is involved in several projects on human biological samples; as an example 
we are currently performing molecular investigations on blood, to detect tumor cells in 
patients with melanoma and breast cancer.  
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My work specifically focused on the technical optimization of molecular methods in urine 
samples. This study was possible for our collaboration with the Department of Urology of 
Cattinara Hospital of Trieste that provided the clinical samples.  
At present the cytologic diagnosis of transitional cell carcinoma of the bladder is based on 
investigations prompted by the discovery of hematuria or the presence of atypical cells in 
the urine. However these abnormalities can also occur in association with banal 
inflammatory conditions, giving false positive results. On the other side, low-grade tumors 
may produce false negative results in voided urinary cytology between 25 and 70% of the 
cases.  
Recents findings (Gelmini et al., 2007; Okegawa et al., 2003; Weikert et al., 2005) showed 
that RNA from urothelial cells shed in the urine can be used as a precious source for gene 
expression analysis. Total RNA extracted from urothelial cells in fact is not completely 
degraded but results accessible to extraction and to subsequent quantitative detection.   
Our preliminary experiments in which progressive dilutions of exogenous T24 cells were 
added to healthy donor urine samples and incubated in reproduced physiological 
conditions (37°C for 1-3-6 hours) showed that a consistent reduction of RNA yield from 
urine samples was not due to a loss in nucleic acid integrity but to the lysis of cells 
followed by the release of RNA in the urine. 
 
2.1 Technical optimization 
The first optimization tests were performed to develop a rapid and efficient extraction 
approach that could replace the more time-consuming guanidinium-based protocol 
(Chomczynski and Sacchi, 2006). 
The development of the new experimental extraction kit was in collaboration with 
Macrochip company, dedicated to the research in molecular diagnostics. 
Our experimental spin-column based approach meets the requirements of improved 
sensitivity and efficiency that are essential requisites for a wider application even in 
clinical practice.  
We found, in fact, that our extraction method is more sensitive than the classical protocol 
when few cells are used; this is effectively the most common situation when urothelial 
cells are collected from voided urine of patients. Nevertheless, this new approach is clearly 
faster because reduces the time for urine processing (one day vs two days).  
Furthermore, complemetary experiments in our laboratory showed that the diatomaceous 
earth-based RNA extraction is absolutely comparable in terms of efficiency and sensitivity 
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to extraction performed by means of the more expensive silica gel or other resins. This is 
another critical aspect that makes our experimental prototype a valid approach for the 
standard diagnostics. This experimental kit was successfully used in a clinical study that 
was published in collaboration with the Department of Urology of Cattinara Hospital 
(Siracusano et al., 2005). In this study total RNA extracted by this procedure was used for 
gene expression analysis of three candidate biomarkers (hTRT, CK20 and CD4) for 
detection of bladder cancer recurrences. The gene expression analysis showed that the 
molecular detection of multiple tumor markers in voided urine cells could represent a good 
complementary test for non-invasive diagnosis of bladder cancer. 
The next optimization step involved the development and validation of an alternative 
mRNA expression detection method that could overcome the problems associated to the 
use of radioactive material for clinical use.  
Radioactive-based detection methods are very sensitive but they present some risks 
associated with the use of radiolabelled material. Besides, the use of radioactive material  
is not allowed in the majority of the medical centres. For the reported problems the 
application of molecular analyses to the clinic environment need to develop methods 
available in every hospital. As several diagnostic kits exploit a modified ELISA 
colorimetric quantification (ELOSA), we tried to optimize this approach in our laboratory 
using the above-mentioned panel of three target genes (Siracusano et al., 2005). 
Telomerase is the ribonucleoprotein enzyme responsible for the production of telomeres 
and for protection of their integrity during DNA replication (de Lange, 1994). The catalytic 
component of telomerase (hTRT) is totally repressed in most somatic human cells and is 
present at very low levels in high replicating normal cells, but it’s newly expressed in 
several human tumors (Gelmini et al., 2000; Lee et al., 1998). 
CK20, constituent of the intermediate filaments of epithelial cells, is expressed in 
gastrointestinal epithelium, as well as in normal urothelium (Inoue et al., 2001). In 
neoplastic urothelial cells this restriction is lost, and CK20 mRNA expression can be found 
in all layers (Harnden et al., 1995). For this reason recent studies tried to detect the 
expression of this gene in exfoliated uro-epithelial cells in the voided urine of patients with 
transitional cell carcinoma (Christoph et al., 2004; Inoue et al., 2001; Rotem et al., 2000).  
CD4 antigen is specific for tumor infiltrating lymphocytes and it has been demonstrated 
that infiltrating T cells play an important role in tumor related immunity (Mumberg et al., 
1999).  
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In our preliminary experiments we found that ELOSA method could be a good substitute 
to the radioactive detection method, especially for the sensitivity. For these experiments we 
used both a cell line system and voided urine from hospital patients. 
Each gene system required a “personalized” analysis but we found a common behavior for 
the detection of all the target genes. In particular we noticed that a high amount of target 
inhibited the signal detection, as well as higher probe concentrations (superior to 250 ng 
per well) did not improve the sensitivity. 
Due to its high sensitivity at lower mRNA concentrations, ELOSA method may represent 
in the next future a good substitute for the radioactive approach and a good compromise to 
be used in detection of genes in biological fluids. 
The colorimetric approach gave however a limited linear range: this clearly reduces the 
spectrum of quantification data that can be used.   
Another limitation in the use of ELOSA plates is due to the rapid expiration of the 
reagents, in particular the phosphorilated probes, both in solution and linked to the well 
surface. This problem, if not properly considered, may give false negative results in 
quantification signal.  
In conclusion, this non-radioactive approach may represent a promising solution for gene 
expression analysis but further experiments or implementations in the technique are 
necessary for supporting its use, first in clinical research and then in clinical practice. 
 
3. MOLECULAR METHODS FOR GENE EXPRESSION ANALYSIS IN 
ARCHIVAL TISSUES 
The second and more consistent part of my study was focused on the technical 
optimization and clinical application of molecular methods for gene expression analysis in 
archival material. This work meets one of the main objectives of the IMPACTS 
(Integration of Molecular Pathology And Cell and Tissues Structure) European Project in 
which my laboratory is directly involved.  
The IMPACTS Coordination Action in functional genomics research (see website: 
http://www.impactsnetwork.eu/ for more details), developed within the European “Sixth 
Framework Program”, could give a consistent solution to the difficulties and complexities 
found in the clinical approval of molecular markers through the definition of common 
guidelines for a reliable clinical application of molecular approaches  to archival material. 
In this context, the large group of 20 European centres headed by pathologists from 11 
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countries represents the ideal dynamic interface to translate molecular pathology research 
into clinical practice through the use of archived tissues. 
The histopathology archive represent a vast, well-characterized historical collection 
covering virtually every disease and thus optimal for retrospective studies (Lewis et al., 
2001). Furthermore, these precious archives have become in the last decades widely used 
for molecular analyses on DNA and, more recently, on RNA and proteins thanks to the 
rapid advances of molecular approaches. 
In the clinical practice a large number of tissue samples are routinely taken from patients 
during surgical interventions, bioptic examination or autopsy. 
These specimens are fixed (usually in formalin) as soon as possible to avoid autolysis and 
putrefaction and then paraffin-embedded to be cut for the histological examination. After 
few sections are cut, most of the tissues are stored for decades in the hospital pathology 
archives and for this reason they are called “archive tissues”. Fixation and embedding of 
tissues guarantee their preservation at room temperatures over years. 
It is possible to estimate that in the last twenty years at least half billion cases were stored 
in the European hospitals, and in most of those multiple tissue samples are stored. 
The great availability of specimens with clinical data and long follow-up times, associated 
with the advent of molecular methods that allow efficient extraction of DNA, RNA and 
proteins make the archival tissues the ideal material for clinical and molecular 
retrospective analysis. This event can accelerate the process of translation of the basic 
knowledge in molecular cancer biology to molecular medicine.  
The main objectives of this Coordination Action correlated to a comprehensive use of 
archival material, are:  
A- To analyze the present knowledge and use about molecular analysis in archive’s human 
tissues in Europe and to propose method validation and standardization: The objective is 
to explore the range of technical availability and reproducibility of these new methods for 
research in functional genomics and clinical application. To establish a more organized 
European research effort the European scientists working in this field are meeting in order 
to compare the different experiences. There are not common protocols for some of these 
molecular analysis in AT (archive tissues) and every laboratory has its own experience. 
After this it will follow the final decision about the technical protocols for DNA, RNA and 
proteins to test for intra- ed inter-laboratories comparison. (this objective is described in 
more detail in the next paragraph). 
 79
Discussion 
B- To disseminate in European laboratories validated and standardized methods with 
good practice rules: The validated protocols will be collected and disseminated in 
European pathology laboratories. This dissemination is a prerequisite for multicentric 
future researches and more diffuse clinical application. 
C- To point out future perspectives of functional genomics and proteomics at research and 
at clinical level: now functional genomics studies are often performed in cell lines or 
animal models. To speed up the introduction of the wide molecular knowledge in the 
clinical practice it is useful the translational research working directly with human tissues, 
especially with AT that are present in very large collection in the archives of every 
European hospital. The future of medicine is oriented to a personalized type of therapy and 
archive tissues are the best material to study disease outcomes with very long follow-up 
time. Even more, these tissues are part of the clinical routine for histopathology 
examination to obtain a final diagnosis. Only after this it could be possible rising questions 
that can be solved with molecular analysis allowing a personalized type of diagnosis, 
prognosis and therapy. This will ensure a very rapid application of advanced genomics 
research results to the clinics for the health of European citizens.  
D- To establish bioethical guidelines for the correct use of human archive tissues in 
research and clinical practice: A group of international bioethics experts will be invited to 
discuss the issue with pathologists, clinicians and other stakeholders. Comparing different 
bioethical national laws, their usual application and new orientation is of pivotal 
importance for European research on human tissues. The final goal is to propose guidelines 
for multicentric studies. 
E- To explore the possibilities to organize archive's tissues banks for future researches: the 
already existing archives can be organized to obtain a sufficient number of cases for future 
multicentric translational researches on specific diseases (homogeneous stage tumours 
case-study, rare tumours …). 
F- To promote technology innovation in archive tissues molecular analysis in 
collaboration with biotechnology industries: in the near future new knowledge will be 
disseminated and translated into new therapy protocols and clinical practice, that will also 
stimulate collaboration with biotechnological and pharmaceutical companies. It is also 
necessary to simplify and to increase specificity and sensitivity of the technology, which 
means multidisciplinary collaboration with specialized research centres and companies 
involvement. Specific biomarkers for diseases prognosis and therapy will be defined and 
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validated in the future research programs proposed by the action participants. These 
biomarkers will be the base for the next generation diagnostic kits.  
 
The confirmation for the urgent need of a standardization and technical optimization of 
commonly used molecular procedures applied to archival material (objective A) came from 
the first IMPACTS meeting held in Trieste the last year. In this occasion some concrete 
problems in the application of molecular approaches to archival samples emerged. They 
were associated in particular to the extreme variability of protocols that each European 
laboratory uses for tissue processing (pre-analytical phase) and the subsequent molecular 
analysis on DNA, RNA and proteins (analytical phase). It also emerged that many 
technical problems are exacerbated by tissue-dependent factors (limited tissue availability, 
tissue composition, type of tissue...), that should always be taken into account. 
The combination of these critical operator-dependent and indipendent problems may 
deeply affect the performance of the molecular investigations and prevent the reliable 
comparison of results between laboratories, resulting in a consistent loss of precious 
molecular information.  
One of the most debated aspect on which my PhD thesis focused was the quantitative 
mRNA expression analysis 
The gene expression pattern of a cell or tissue determines structure and function. Gene 
expression is a dynamic process which reflects both temporal and lasting changes in the 
biological state of cells, organs and organisms. Thus, it’s clear that gene expression 
analysis may be an important complement to the traditional methods of laboratory 
medicine and it can be used as an approach for biomarker detection. 
A number of studies have shown that archival material is amenable to the analysis of 
mRNA and several protocols have been established for the retrival of mRNA from 
routinely processed FFPE tissues (Lehmann and Kreipe, 2001; Macabeo-Ong et al., 2002; 
Specht et al., 2001; Stanta et al., 1998b); however no standardized methods have been 
defined and the more recent high throughput technologies did not give yet consistent 
clinical results. 
As an example, cDNA microarrays allowed the detection of expression profiles and gene 
sets that are prognostic and/or predictive of outcome of many cancer (Hayes et al., 2006; 
van de Vijver et al., 2002) but, unfortunately, genes identified by these studies show only 
slight overlap. The major concern related to the use of microarrays platform is the 
requirement of high-quality RNA, generally derived from frozen samples. A recent paper, 
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by Penland et al, demonstrated that only a minority of FFPE blocks could be analysed by 
microarray (Penland et al., 2007) 
In contrast with microarray-based gene expression analysis, quantification of expression 
levels of individual genes using endpoint or realtime RT-PCR (qRT-PCR) in archival 
material is now well developed. PCR-based methods in fact can tolerate even extensive 
degradation, as long as the extraction technique is properly adjusted and the amplicon sizes 
are kept small. Furthermore, as the required amounts of input RNA are small, also 
microdissected specimens can be successfully used (Specht et al., 2002; Specht et al., 
2001). 
A concrete clinical application of realtime PCR in FFPE is offered by Oncotype DXTM, a 
realtime PCR-based assay that includes 16 breast-cancer related genes and 5 reference 
genes (http://www.genomichealth.com/oncotype/default.aspx). This prognostic approach, 
resulting highly reproducible and quantitative, is a significant improvement over classical 
immunohistochemical technique (Paik et al., 2004). 
 
3.1 Technical optimization 
The following discussion referred to gene expression analysis reports the critical points 
from tissue processing to data acquisition, that were talked over during the meeting and 
explains in more detail which of them were subsequently investigated in our laboratory. 
3.1.1  Pre-analytical treatment of tissues 
Pre-analytical treatment of tissues is one of the most variable and debated questions in 
molecular analysis of tissues because many factors are integrally involved (Srinivasan et 
al., 2002) and no common guidelines between laboratories have been defined yet. Pre-
analytical treatment is related to the lapse of time between ablation of tissues and tissue 
fixation, to fixation procedures and to the post-fixation effects.  
• Pre-fixation time 
Fixation procedure is usually rapid but not immediate. The pre-fixation time involves both 
the interval of time during intervention and organ removal, and the lapse of time from the 
surgical table to the pathology laboratory.  The major problem in this whole lapse of time 
is related to the hypoxic conditions of the tissue, that in surgical specimens, because of the 
closure of the blood vessels during the surgical treatment, can also start before the ablation 
of tissues. Thirty minutes are usually considered, by convention, the limit for a 
conservative treatment of the tissues before fixation or freezing (Huang et al., 2001). 
Anyway, as significant biochemical alterations occur in tissues within 10 minutes after 
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anoxia, the prefixation time should be kept at the minimum to minimize nucleic acid and 
protein degradation. Changes in local pH, the size of the tissues and the time for reduction 
of tissues to small fragments for the histological examination are to be considered as pre-
fixation variables. 
• Fixation step 
Among the different fixatives that have been developed and tested throughout the years, 
formaldehyde as a 10% neutral buffered formalin solution, although highly toxic and 
carcinogenic, still remain the most widely used fixative because it preserves a wide range 
of tissue components. However, formalin is a cross-linking agent that alters and fragments 
nucleic acids, thus impairing extraction efficiency and quality of nucleic acids (Srinivasan 
et al., 2002). Only 3% of FFPE derived RNA in fact is considered accessible to reverse 
transcription (Godfrey et al., 2000). Besides, the overall rate of formalin-induced 
modification of nucleic acids is dependent on changes in the concentration, temperature 
and pH of the fixative (Cross et al., 1990; Douglas and Rogers, 1998).  
The time of fixation with formalin has not been definitively standardized. During the week 
infact, the histopathology lab procedures are quite standardized but any variation can 
double the time of fixation and this fact is not usually reported. For formalin fixation this 
variable is especially important as its penetration changes during time and the number of 
crosslinks among proteins increases with the time of fixation.  
Alternative fixatives have been introduced to overcome the problems met with formalin, 
maintaining a good tissue morphology, but also good preservation of macromolecules. 
Among them there are the home-made fixatives, such as the alcoholic fixatives [ethanol 
(Perlmutter et al., 2004) and methanol], mixtures of fixatives [(Carnoy’s, methacarnoy 
(Lee et al., 2006), acetone, , Bouin(Gloghini et al., 2004), tannic acid], zinc-based fixatives 
(Lykidis et al., 2007) and commercial patented fixatives [FineFIX (Stanta et al., 2006), 
UMFIX (Vincek et al., 2003), RCL-2 (Delfour et al., 2006)] and HOPE (Olert et al., 
2001)]. For some fixatives, fixation can be sensitively improved in a microwave assisted 
processing  (Barrett et al., 2004; Cox et al., 2006). 
- In the present work we analyzed three different fixatives and assessed their effects on 
RNA quality and quantity by realtime quantification.  
We compared the commonly used formalin with two alcohol-based fixatives, one toxic 
home-made fixative (methacarnoy) and one completely non-toxic new commercial fixative 
(FineFIX, by Milestone). For this comparative experiment we used an homogeneous cell 
line-based system, as already performed by others (Koch et al., 2006). Because RNA 
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submitted to these three fixations derived from the same culture bottle, qualitative and 
quantitative changes in RNA reflected only the differences between the selected fixatives.  
It must be noticed that the same “artificial” system was also used to investigate the 
performance of some of the most used methods for RNA quantification and integrity 
assessment. This part will be discussed later. 
We found that each fixative determines different effects on RNA quality and quantity. 
Quantitatively, it seems that formalin fixation is the most aggressive with the respect of 
RNA yield, reducing drastically its recovery since after 3 hours of fixation. On the other 
hand the two alcoholic-fixatives seem to be more conservative, especially FineFIX. This  
behaviour agrees with other reports (Shibutani and Uneyama, 2002; Stanta et al., 2006). 
The use of alcoholic fixatives, and in particular FineFIX, seems to be important in case 
RNA has to be extracted from microdissected sections or from small biopsies. 
The gel electrophoretic results clearly show that the three fixatives determine different 
degradation patterns. Visual observation of the rRNA bands seem to indicate that in 
formalin fixation a rapid decrease of RNA quantity is joined by a progressive reduction of 
RNA integrity. In the other two cases data interpretation is more difficult: FineFIX fixation 
in fact seems to be the least conservative as very weak rRNA bands are present even after 
1 hour of fixation, while methacarn fixation seems to preserve only 28S rRNA. This 
contrasts with what is generally found for rRNA degradation process, where a more rapid 
degradation of larger subunit is usually observed (Strand et al., 2007). 
The following real-time gene expression analysis for the two housekeeping genes clearly 
showed that the integrity results are consistent with the concomitant decrease of PCR 
signal only for formalin fixed samples. 
On the contrary, rRNA degradation seems not to correlate with mRNA integrity when cells 
are fixed with the two alcohol-based fixatives. This result shows that conventional integrity 
assessment approaches that rely on rRNA ratio are not reliable at all to predict the effective 
accessibility of mRNA subpopulation to following analysis. This is consistent with what 
was found by others (Imbeaud et al., 2005) who demonstrated the inconsistency of the 
28S:18S ratio to assess RNA quality.  
If we compare the effects of fixation on quantitative ratios, we notice that formalin fixation 
determine a progressive overestimation of ATP5B and HPRT gene expression risults if 
compared with the not-treated sample. Alterations in the quantitative ratio were already 
observed (Godfrey et al., 2000; von Smolinski et al., 2005). These progressive Ct 
differences may prevent the possibility to correlate the expression levels between genes in 
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different samples because the detected differences could be the result of the fixation time 
and not of real gene expression variations.  
These differences could be due to increasing alterations determined by formalin at the 
adenine level of the target sequence (Masuda et al., 1999). Moreover, it is conceivable that 
in formalin fixation the progressive alterations of quantitative ratios are also determined by 
the consistent loss of target mRNA. The low abundance of target mRNA, in fact, increases 
the probability of random annealing of the primer to its template (“Montecarlo effect”) 
(Bustin and Nolan, 2004). 
This means that we can compare gene expression levels in material fixed in formalin for 
different times only after a standardization of the degradation levels by means of a reliable 
HKGs (Tricarico et al., 2002). In particular, it would be recommended to choose the 
HKG/panel of HKGs on the basis of the expression levels of the target genes (Thellin et 
al., 1999). This may reduce the quantitative alterations induced by the Montecarlo effect. 
Although non crosslinking fixation should avoid sequence alterations, a modification in the 
quantitative ratios was observed even for FineFIX and methacarnoy fixation. However 
these alterations seem to be not correlated to the fixation time. This aspect could be 
exploited when comparative gene expression analysis is performed between archival 
samples of unknown or variable origin. 
Furthermore, the interesting results found in this homogeneous model needs to be validated 
in archival tissues. These experiments are in progress in our laboratory. In order to remove 
operator variability during the fixation process, we are performing tissue fixation (with 
formalin, FineFIX and methacarnoy) by ourselves applying the same prefixation 
conditions. Tissues are collected in ice from the surgical theatre immediately after the 
excision and then fixed. These specimens are then submitted to molecular analysis. 
• Post-fixation 
Even if few studies have deeply investigated this problem, it’s conceivable that oxidation 
of tissue sections may decrease antigen recognition and may also have a similar effect on 
nucleic acid recovery or retrival (Srinivasan et al., 2002). A recent work in fact showed 
that RNA fragmentation in FFPE tissue continue to occur after specimens are dehydrated 
and embedded in wax (Cronin et al., 2004). In our opinion this phenomenon could be 
dependent on the quality of paraffin used for embedding, but the possibility of a partial 
reactivation of endogenous RNases  before embedding cannot be excluded. At the moment 
experiments on very old blocks examined in comparison with recent inclusions can be 
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performed only on formalin and methacarnoy fixed tissues because FineFIX has been 
entering in the routinely hisotological practice in some institutions since 6-7 years. 
 
3.1.2 Analytical phase  
The analytical phase includes all the procedures that move from the cut of paraffin blocks 
to the acquisition of molecular data. 
• RNA extraction 
If we refer to home-made procedures, no common protocols  for RNA extraction (but even 
for DNA and proteins) are used on FFPE tissues and every laboratory brings its own 
experience, making the inter-laboratory comparison of results very difficult.  
Even though all laboratories agree in the use of proteinase K-based protocol for RNA 
estraction (Koch et al., 2006). The use of proteinase K is essential for a complete 
solubilization of FFPE sections as this enzyme destroys proteins and allows the release of 
RNA from the cross-linked matrix (Lewis et al., 2001; Masuda et al., 1999). Differences 
are related to the time (from 12 to 72 hours) and temperature of digestion (45°C-65°C), 
and for nucleic acid purification (classical phenol/chloroform ectraction or spin-column 
based extraction). Perchè prot K(Lewis et al., 2001) 
This specific technical problem will be handled in the next future by a comparison of the 
methods among different laboratories of the IMPACTS group. 
• RNA quantification 
An accurate quantification of input RNA is essential when a reference gene validation 
experiment must be performed before the gene expression analysis(Huggett et al., 2005). 
In fact many reports have demonstrated that even the classic reference genes can vary 
extensively depending on the specific experimental conditions (Dheda et al., 2004; 
Tricarico et al., 2002), and the choice of an inappropriate reference gene can result in 
unreal findings (Dheda et al., 2005). This is particularly worrying when gene expression 
analysis is performed on clinical samples. 
For this reason we compared three commonly used methods for total RNA quantification, 
two spectrophotometric approaches and one fluorescent method. For this analysis the 
already described cell line-based system was used.  
From this experiments we deduced that the method of choice for quantification of RNA 
from archived samples resulted the spectrophotometric approach. On the contrary, Agilent 
Bioanalyzer results did not correlate with the others, for this reason we not consider it a 
reliable quantification method. 
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Besides, Nanodrop resulted more reliable than standard spectrophotometric method for 
purity assessment: this is deduced looking at the 260/280nm ratio referred to the fresh 
sample extracted with Trizol. As it was considered the “golden standard” specimen, a high 
260/280nm value (>1.8) was expected in any case: this value was confirmed only by 
Nanodrop measurement (1.93). 
For all these reasons, in our opinion Nanodrop resulted the best choice. Furthermore, it’s 
the most practical method and requires very low sample amount (1μl), which is very useful 
when using FFPE and it’s very reproducible because no sample dilutions are necessary. 
• Assessment of RNA degradation levels 
Determining the integrity of RNA starting material is a critical step in gene expression 
analysis, as RNA integrity may have a significant impact on expression results (Fleige et 
al., 2006). Conventional electrophoretic methods, however, are often not sensitive enough 
and disposed to interferences from contaminants present in the sample (Imbeaud et al., 
2005). The classical gel electrophoresis is highly sample consuming (this represents a 
crucial problem when low amount of RNA is avalable, such as for microdissected samples 
or small biopsies) and the visual assessment of 28S/18S bands is often subjective and 
inaccurate. 
In agreement with other reports (Dumur et al., 2004; Schoor et al., 2003; Schroeder et al., 
2006; Skrypina et al., 2003), our results on differentially fixed cells show that the mere 
integrity analysis of total RNA from fixed samples by observation of 28S/18S subunits is 
not informative about the effective accessibility of mRNA subpopulation. In our 
experiments it was evident especially for alcoholic fixation. 
In order to define the most accurate method for assessment of RNA degradation we 
compared the results of the conventional electrophoretic gel with those obtained with 
Agilent Bioanalyzer using RNA derived from non fixed and fixed cells.  
Agilent results by rRNA “ratio method” gave results consistent with the electrophoretic 
pattern, but not with the expression of the genes. For this reason we do not consider it a 
reliable approach. Agilent results by visual and RIN methods were consistent with those 
obtained with conventional gel electrophoresis, confirming the different patterns of 
degradation for the different fixatives. This agrees with Nolan et al., who analysed 
successfully RNA with unavailable RIN number even for long stretches of amplification 
(Nolan et al., 2006). The authors reported in fact that the relationship between RIN number 
and transcript quantity (by RT-PCR) was different for different tissues and there was not a 
predictable relationship between these factors. 
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Finally, the smear analysis correlated with the visual assessment but gave further useful 
information about fragment distribution that were not easily derivable from the 
electropherogram analysis. For this reason we consider this smear analysis the method of 
choice to predict the performance of the following real-time quantitative PCR analysis.  
This analysis in fact highlighted the real presence (even after prolonged fixation), of 
fragments between 100 and 300 and  between 500 and 3000 bases for FineFIX fixation and 
between 3000 and 5000 bases for methacarnoy fixation. On the contrary, it confirmed the 
strong degrading effects of formalin. 
These hypotheses were also confirmed by the endpoint PCR-based approach that, together 
with smear analysis, resulted the most suitable method for RNA degradation assessment. 
Successful PCR amplification of long fragments (more than 600bp) in fact demonstrated 
that RNA from cells treated with alcoholic fixatives is effectively more intact than that 
extracted from formalin. 
• DNase treatment 
A frequent cause of false positives in RT-PCR is the amplification of contaminant genomic 
DNA (gDNA) in RNA preparations. Because of the sensitivity of PCR technique, a single 
copy of a genomic sequence can be theoretically detected; this phenomenon is exacerbated 
when tested genes present non-functional pseudogenes at DNA level. Their sequences are 
similar to mRNA, for this reason DNA removal by DNAse digestion is often a necessary 
step.  
In our experience we found that DNase treatment followed by heat inactivation in specific 
conditions can be a good substitute to the more common phenol/chloroform extraction. 
In our opinion it represents the method of choice when RNA is extracted from small or 
microdissected samples because the precipitation step, with its low yield, is skipped 
allowing a greater recovery of RNA.  
We noticed that the presence of  the inactivated DNase enzyme, its buffer and EDTA (at 
low concentration) does not affect the subsequent RT-PCR analysis, as demonstrated by 
the amplification curves. 
The slight differences in Ct values obtained by the two methods may be due to the different 
approaches that were used for the upstream quantification. The spectrophotometric 
measurement of RNA after DNase treatment followed by heat inactivation was excluded as 
the presence of the enzyme and buffer was shown to interfere with the reading. 
Concentration in this case was determined taking into account the spectrophotometric 
reading before treatment and the new final volume of reaction. 
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• Reverse transcription 
cDNA synthesis from RNA is a critical step in gene expression analysis and it’s a major 
source of variability for all RT-PCR assays. Reverse transcription yields can vary up to 
100-fold depending on reverse transcriptase (Stahlberg et al., 2004b), priming strategy 
(Stahlberg et al., 2004a) and quantity of RNA used (Chandler et al., 1998), and the 
variation can be also gene dependent (Stahlberg et al., 2004a; Stahlberg et al., 2004b). In 
the use of RNA from FFPE samples this technical variability is further exacerbated by 
intrinsic tissue heterogeneity, by the presence of inhibitory co-purified components (Nolan 
et al., 2006) and by variable degradation pattern of extracted RNA. All these variables 
explain the huge and contradictory results reported by different research groups working 
on supposedly similar samples.  
For all these reasons the use of the same extraction and RT strategy combined with the 
same amount of starting material is important to obtain more comparable and reproducible 
results.  
In this study we tested the reproducibility and sensitivity of some reverse transcription 
protocols in order to define the most efficient and reproducible approach for RT-PCR for 
both high and low expressed genes in archive specimens. 
The template protocol that we used for the comparison was taken from Godfrey at al 
(Godfrey et al., 2000) as this procedure gave in our opinion a sensitive improvement of the 
RT-PCR results. We think that the additional MgCl2 required by this protocol represents a 
good expedient when previous DNase treatment was stopped by heat inactivation because  
it compensates the kelating effects on Mg2+ by the residual EDTA in the RNA solution. 
This priming strategy, involving the random hexamers, was compared with a new strategy 
involving the random pentadecamers (Stangegaard et al., 2006). It has been shown in fact 
that substitution of random hexamers with random pentadecamers can yield at least 2-fold 
increment of cDNA in comparison with 6-mers use. In order to validate this hypothesis on 
FFPE, we used low (0.167nmol/reaction, corresponding to the usual concentration of 
random hexamers) and high (3.35 nmol/reaction, corresponding to the proposed 
concentration of random pentadecamers) equimolar quantities of both random primers. 
These combinations were finally compared with a “multiplex” AMV-based protocol, in 
which a mix of specific reverse primers was used. It is well known that target specific 
primers are the most specific and sensitive method to convert mRNA into cDNA (Lekanne 
Deprez et al., 2002; Nolan et al., 2006), for this reason we included this strategy in our 
experiment. However, the association of AMV with a single reverse primer requires 
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separate priming reactions for each target genes. This could represent a problem if RNA 
quantity is a limiting factor in the analysis as in FFPE tissues. For this reason we decided 
to performe a variant of this approach using a mix of reverse primers. Our results 
combining the sensitivity, efficiency and correlation confirmed that the best solution for 
cDNA synthesis is the association of MMLV with both random primers. This finding also 
shows that the higher sensitivity of the RT is not achieved by the use of random 
pentadecamers but exclusively by the use of 20-fold more concentrated primers (both 6-
mers and 15-mers). Furthermore, this technical improvement is not gene-dependent (better 
results were seen for the four target genes) but is strategy-dependent. This contrasts with 
the results by Stahlberg et al (Stahlberg et al., 2004a), who found a high dependence of the 
priming strategy efficiency on the tested gene. The low efficiency found for the 
combination of AMV with the mix of specific primers could be due to an inhibitory effect 
determined by this priming strategy. The same reaction, performed using four separate 
reverse transcriptions (one specific primer per reaction) did not show this inhibition (data 
not shown). 
The use of random primers (at high concentration) instead of specific primers represent is 
then recommended because the same reverse transcription reaction can be used for the 
detection of several genes in the same sample. This is very convenient when starting 
amount of RNA is very low, as in the case of FFPE or small biopsies.  
• Quantification 
Among the various methods for qRT-PCR, TaqMan assays with the dual-labeled 
fluorescent probes are the most widely used, although SybrGreen assays have also been 
successfully employed on FFPE (Abrahamsen et al., 2003). TaqMan chemistry is 
considered the best choice for gene expression analysis in FFPE tissues because the use of 
a specific probe reduces problems associated with nonspecific amplification and primer 
dimer formation, and allows expression detection even when the target concentration is 
very low (<1000 copies) (Nolan et al., 2006).  
In this study we wanted to demonstrate whether a validated SybrGreen chemistry may be 
used as a more economic substitute to TaqMan probe-based approach. This should be very 
convenient when performing analysis on large case studies. 
In order to reduce the variability between the two methods, the same primer sequences for 
ATP5B and HPRT were used. A critical parameter was the amplicon length, that was 
rigorously kept between 60 and 100bp for all the target genes. In these conditions in fact 
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the amplification efficiency and sensitivity in FFPE are similar to those found in fresh 
material (Lewis et al., 2001; Specht et al., 2001). 
For SybrGreen chemistry, a strong validation of amplification conditions was performed. It 
involved not only the primer concentration and the annealing temperature but also the 
denaturation temperature of the whole PCR reaction (we noticed in our systems that 
approximately 0.5 Ct can be gained once it’s optimized) and the fluorescence reading 
temperature (the inclusion of this fourth step in PCR program considerably reduced the 
primer dimer formation). 
From this preliminary experiment, we can speculate that SybrGreen chemistry can 
substitute TaqMan-based approach in gene expression analysis: the two methods overlap in 
terms of efficiency, as already seen by others (Schmittgen et al., 2000), and in one case 
SybrGreen chemistry is even more sensitive (see the results for HPRT gene). The lower  
sensitivity of TaqMan approach in HPRT gene expression analysis may be due to aspecific 
interactions of the probe with primer dimers, which reduces its availability for the specific 
target amplification. However the wider dynamic range for TaqMan chemistry seems to 
confirme that it remains the best choice when a reliable detection of even low copy number 
genes (with Ct > 34) is required. 
 
3.2 Future perspectives 
The second IMPACTS meeting was organized in February 2008 in Munich. 
In that occasion the results of the above-mentioned “home-made” protocols and the 
experience of the other 20 laboratories have been deeply discussed from which the 
preliminary guidelines of the most appropriate and reliable molecular methods on archival 
material were  proposed.  
In this occasion other critical processes were discussed. For the pre-analytical treatment of 
tissues, it has been decided to validate the procedure about the transportation of surgical 
specimens from surgery to pathology in vacuum bag (Bussolati et al., 2008). 
For the analytical phase, it has been proposed to uniform and validate the DNA and RNA 
extraction protocols, as too many contrasting experiences emerged about these procedures. 
Finally Prof. Giorgio Stanta,  coordinator of the European project suggested starting with 
the second and third part of the guidelines by collecting the list of the commercial kits from 
all the laboratories, in order to compare their real effectiveness in archival material with 
the reliability of the corresponding “home-made” protocols. 
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3.3 Application of molecular methods to gene expression analysis in two archival case 
studies 
In this section of the study two archival case studies were collected for the quantification 
of candidate biomarkers using the molecular approaches for gene expression analysis. 
 
3.3.1 Breast cancer case study 
Several clinical and pathological factors have been proposed to predict the recurrence of 
breast cancer. However, at the present time it is not possible to predict recurrence versus 
no recurrence at an individual level.. Different single molecular markers have been 
assessed in the past 20 years, but failed to be considered for clinical use for various reasons 
(Pusztai et al., 2006). Microarrays studies have identified expression profiles and gene sets 
that are prognostic or predictive, or both for patients with breast cancer. Comparison of the 
lists of genes derived from these studies shows only a slight overlap probably due to 
differences in the cohorts of patients, microarray platforms and mathematical methods of 
analysis (Fan et al., 2006). In the present study, carried out on 80 women with infiltrating 
duct carcinoma of the breast, quantitative endpoint RT-PCR was performed for a set of 22 
genes involved in cell senescence, malignant transformation and tumor suppression. This 
study confirms our previous findings on the expression level of CDK2, CDK4 and 
CDC25a in breast cancer progression (Bonin et al., 2006) (Bonin et al., 2006) and their 
correlation with recurrences. As previously reported (Bonin et al., 2006), CDK2 over-
expression seems to have an influence on patient’s survival both by uni- and multi-variate 
analysis, while data on CDC25a and survival were confirmed only by univariate analysis. 
In our study, Cox proportional hazard analysis did not identify tumor stage as significantly 
affecting survival in these patients (p= 0.1). Patients’ survival was analyzed by the Cox 
proportional hazard regression method. Here only those genes that showed a significant 
level of survival between the two groups are discussed.     
Cox proportional hazard analysis identified different molecules involved in patients’ 
survival. In particular, our results showed that patients with a higher expression level of 
HER2 and/or PI3K, and a lower expression level of AKT seem to have the worst outcome. 
Our data agree with previous reports: it is well known that alteration in the PI3K/AKT 
signalling cascade is common in human cancers and results in hyper-activation of the 
pathway that leads to tumor progression (Fresno Vara et al., 2004). In particular, our data 
associate a worse outcome to patients over-expressing HER2 and/or PI3K but not AKT. 
The association of higher AKT3 mRNA expression level with better prognosis shown in 
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our study is discordant with a previous paper (Tokunaga et al., 2006). A possible 
explanation of this discrepancy is related to methodological issues, since Totunaka et al., 
detected AKT in its activated status, ie the expression of phosphorylated AKT by IHC.  
Our results show that patients with high RAF-1 status had a decreased disease survival. 
These data agree with previous findings by Mewani et al. (Mewani et al., 2006). 
It is well documented that RB pathway plays a critical role in cell cycle progression (Sherr 
and McCormick, 2002). Our latest results on RB expression level and survival indicate a 
protective role of this molecule in breast cancer progression. Patients with high RB seem to 
have a longer survival time. Our findings agree with Derenzini et al. (Derenzini et al., 
2007). 
Moreover our data show that the CDK2 and RB expression levels, when combined 
together are well able to predict patients’ survival. The fact that patients characterized by 
high status of CDK2 and low status of RB presented a worse prognosis agrees with the role 
of these molecules in progression of the cell cycle through the G1/S phase and even 
indicated overcoming of this control checkpoint.   
CK8 is characteristically present in luminal cells of a normal mammary gland. A wide 
range of cytokeratin expression is often seen in invasive breast cancer, which may be 
caused by loss of differentiation of the tumor cells (Su et al., 1996). In our study, higher 
expression levels of CK8 were associated in Cox multivariate analysis with better 
prognosis and CK8 has a protective influence on patients’ survival. Our data are 
concordant with the investigation by Fuchs et al. (Fuchs et al., 2002) based on IHC in 
breast carcinomas and breast cancer cell lines. In our case study, CK8 (at high expression 
status) in association with HER2 (low expression status) identifies a group of patients with 
better prognosis. In this group of patients the oestrogen receptor (ER) status was analysed 
by RT-PCR as previously reported (Nardon et al., 2003). The group characterised by high 
expression level of CK8 and low expression levels of HER2 were all positive for ER at 
mRNA level. On the contrary, the other group, defined by the opposite pattern of the two 
markers (high HER2 and low CK8 levels), presented very low or no expression levels of 
the oestrogen receptor. These data agree with the recently reported molecular classification 
of breast cancer (Perreard et al., 2006).  
Of the 22 markers analysed in our study, 15 genes did not show influence on patients’ 
survival. Among them, telomerase components need a comment. This enzyme catalyzes 
the de novo synthesis of telomere repeats, which is necessary for unlimited cellular 
proliferation. The telomerase reverse transcriptase hTRT was detected at mRNA levels 
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both in normal breast and breast cancer tissues (Hines et al., 2005). Recently, Salhab and 
co-workers investigated the expression level of the key telomere related genes in human 
breast cancer and found that hTRT levels predicted the patients’ overall survival (Salhab et 
al., 2007). In our study we did not find any association among telomerase components 
(hTR, the RNA template and hTRT, the catalytic component), pathological parameters and 
patients’ survival. One possible explanation is the normalization methodology used by 
Salhab. Indeed, the authors normalised the expression levels of the telomerase genes 
against cytokeratin 19 (CK19) and not against one or more reliable housekeeping genes. 
This could modify the expression level of the telomerase machinery according to level of 
CK19 expressed in cancer epithelial cells. From our study it seems that telomerase 
expression could be a prerequisite for the early phase of tumorigenesis rather than a 
mechanism connected with progression. The presence and relative abundance of epithelial 
cells expressing telomerase within normal breast tissues could suggest that breast tumors 
arise from these highly expressing telomerase epithelial cells (Hines et al., 2005). 
The molecular tumor progression analysed in the present study shows the natural history of 
the disease, because the enrolled patients were only treated with the same type of surgical 
therapy. Our findings strongly demonstrate that the combination of two pairs of 
functionally conflicting markers (RB and CDK2 on one side, CK8 and HER2 on the other) 
may be divided into subgroups that cover over 50% of the patients and these pairs of 
markers are able to identify subgroups of patients with shorter relapse free and survival 
times from those with long survival without recurrences. Groups characterised by low RB 
and high CDK2 (27% of survival at 5 years and 14% at 10 years) as with low CK8 and 
high HER2 (53% of survival at 5 years and 33% at 10 years) have a higher risk of early 
recurrence and death, suggesting that breast cancer progression in these patients could be 
related to these markers. Moreover, the recognition of these subgroups of patients with 
higher risk of early relapse could have further relevance for the selection of patients to 
submit to therapy against HER2 or also against CDK2 as possible therapy targets. On the 
contrary, those with low CDK2 expression and high RB (68% of survival after 15 years), 
and those with high CK8 and low HER2 (69% of survival after 15 years) present a very 
good prognosis.  
These promising results are preliminary because the real predictive value of these double 
biomarker groups could result only from larger retrospective and prospectively randomised 
studies. For this reason we recently enlarged this case study selecting further 200 duct 
breast carcinomas from the Cattinara Hospital archives. From one point of view, this 
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enriched case study will be useful to confirm the above-mentioned results on candidate 
biomarker discovery. Meantime, the parallel use of the conventional approaches and the 
technical advancements directly on large archival case studies will be critical to validate 
their effective applicability in clinical practice. 
Moreover, a possible use of IHC markers as surrogates for the reported genes could 
represent a further simplification with the prospective of introducing them into routine 
tumor management.  
 
3.3.2 Adrenal gland tumor case study 
Up to now, few clinical studies have accurately characterized the genetic and 
histopathological backgrounds of cortical and medullary tumors because of their rarity. In 
most cases, very limited case studies have been submitted to molecular investigations 
(Lombardi et al., 2006; Slater et al., 2006; Thouennon et al., 2007)and results were not 
comparable between different studies (Bernini et al., 2002). 
With the collaboration with the Surgical Pathology Department of the University of 
Padova, we collected 34 paraffin embedded samples deriving from 15 adenomas, 9 
carcinomas and 10 benign pheochromocytomas. Manual microdissection was also 
performed to isolate the peritumoral component from 5 of these samples. 
Our preliminary study was focused on the examination of the angiogenetic pattern of these 
tumors in order to elucidate its possible role in tumor classification. The impact of 
angiogenesis on tumor progression of endocrine tumors is almost unknown (Favier et al., 
2002; Sasano et al., 1998). However, the hypothesis of its influence on their activity is 
clearly supported by the fact that these endocrine tumors base most of their function on the 
release of hormones into the vasculature. 
In the first part of this preliminary study a gene expression analysis was performed on four 
critical factors involved in the angiogenetic process in order to define the angiogenetic 
pattern in these tumors, compared with the pattern in the healthy counterpart. 
VEGFC and VEGFD ligands were included in our molecular analysis because they are 
important regulators both for hematogenous and lymphatic metastasis, depending on their 
interaction with VEGFR2 or FLT-4, respectively (Plate, 2001).  
Our first results about the angiogenetic characterization of the adrenal gland tumors 
showed that lower expression levels of the two receptors were present in carcinomas if 
compared with adenomas. Conversely, adenomas show a wider range of expression levels 
for all the considered genes, indicating probably that these two receptors do not have a 
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critical role in the angiogenetic behaviour of this benign tumors. Furthermore, these 
findings stress the hypothesis that a contribution of both receptors is essential for tumor 
progression towards malignancy. These results contrast however with the 
immunohistochemical data a recent report (Bernini et al., 2002), that described a higher 
level of positive cells for FLT-4 in carcinoma if compared to adenoma. This may be due to 
differences in the molecular approach used, considering the difficulty to evaluate 
quantitatively the immunohistochemical results.  
The level of expression of VEGFC is not different among the analysed group, so we  
believe that  it has not a critical role in tumoral neoangiogenesis. Conversely, VEGFD 
could be an important factor in the progression towards malignancy, as significant 
differences in its expression levels where detected in pheochromocytomas and carcinomas 
when compared with the healthy counterpart.  
From the expression analyses, pheochromocytomas presented a different pattern only from 
the peritumoral component the benign adenoma. Significant differences were in fact 
detected for FLT-4 and VEGFD when compared with adenomas and healthy component, 
respectively. These results highlight a similar angiogenetic pattern between medullary 
tumors and adrenocortical carcinomas. 
When the expression levels of the four genes were correlated in the different pathological 
groups of the case study a fine equilibrium was detected only in the peri-tumoral tissues. In 
this group all the four target genes were reciprocally correlated (direct correlations were 
found between VEGFR2 and VEGFC and VEGFD, r=+0.63 and r=0.71 respectively, while 
inverse correlations were found between FLT-4 and EGFR2, VEGFC and VEGFD, r=-
0.72, r=-0.62 and r=-0.59, respectively; a strong direct correlation was found between 
VEGFC and VEGFD). The negative correlation detected between FLT-4 and the two 
ligands (VEGFC and VEGFD) could be explained with a negative effect on FTL-4 mRNA 
expression from both the ligands. This is in disagreement with previous results (Roy et al., 
2006). This could be related to the complexity of the angiogenesis regulation process that 
involves the coordinated interaction of many other inhibitory and stimulating factors. On 
the contrary, both ligands seems to have a positive effect on VEGFR2 because of the 
positive correlation detected.  This fact agrees with the data reported in a recent 
review(Olsson et al., 2006). 
In the tumoral groups the previously reported equilibrium was completely lost, indicating 
an effective alteration of the angiogenetic pattern. In particular, both in adenomas and 
carcinomas a positive role in angiogenesis seemed to be played by the two receptors. 
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However, their function seemed to be enhanced by either VEGFC, in adenomas, or 
VEGFD, in carcinomas. It seemed that progression towards benign neoplasia was 
promoted by the acquisition of a new positive interaction between VEGD and FLT-4. 
Progression towards malignancy seems to require another molecular environment: in 
carcinoma, in fact, the molecular pattern of the receptors seems to be mediated by the other 
ligand, VEGFC. Both in adenomas and carcinomas the two receptors are the final positive 
effectors. In pheochromocytomas the contribution of the two ligands is lost but a positive 
correlation between the two receptors is still present. This stresses the critical role played 
by these two candidate markers in the tumoral angiogenetic process in both the medullary 
and adrenocortical tissue. 
In order to elucidate if the altered gene expression levels of these angiogenetic factors may 
have real contribution on the angiogenetic pattern, we compared the mRNA expression 
levels of the four genes with the microvessel density. Recent studies have demonstrated 
that MVD may be used as biomarker for detection of tumor recurrences or as surrogate 
biomarker for the efficacy of the antiangiogenetic therapy (O'Byrne et al., 2000; Singhal et 
al., 1999). However, the extreme variability of the procedures used for MVD count, 
prevent its reliable use in clinical practice (Choi et al., 2005). For MVD count we used the 
most common procedure found in literature, consisting of a first inspection of the slide at 
low-power magnification, followed by the vessel count in the three most vascularized areas 
(“hot spots”) at high-power magnification (Mohammed et al., 2007). 
A strong correlation between MVD and the transcriptional levels of three angiogenetic 
factors (with the exception of VEGFC) was found only in the carcinoma group, showing 
that an abnormal activation of these factors is apparently necessary in adrenocortical 
cancer for the progression towards malignancy. In the other tumoral groups the absence of 
correlations between the angiogenetic factors and the vessel density could be due to the 
secondary role that angiogenesis play in the development of these benign tumors.  
Our results strongly demonstrate the presence of differences in the expression pattern of 
the analysed genes in the different groups analysed. Our data highlighted that there is a 
different behaviour at the mRNA level for the angiogenetic markers in the difeerent 
pathologies of the adrenal gland. Moreover in the carcinoma group the molecular findings 
correlated also with the MVD measurement. Our findings, however, need to be confirmed 
by the analysis of a greater amount of samples, that for these rare pathologies is really 
difficult to recruit. In any case our study agree with a previous report (Chrisoulidou et al., 
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2007) that stressed the importance for these tumors to combine immunohistochemical and 
molecular markers for a sound earlier diagnosis. 
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CONCLUSIONS 
 
Diagnostic and prognostic approaches in traditional medicine are not sufficient to predict 
the clinical behaviour of tumors with the same stage and grade.  
An appropriate application of molecular methods to study cancer processes at cellular and 
at molecular level, also known as molecular medicine, could overcome these limitations. 
Clinically useful biomarkers represent the successful application of molecular methods to 
clinical practice, opening the door to a more personalized vision of medicine. However, 
insufficient expertise at clinical level in the use of molecular methods, the high complexity 
of human biospecimens and their inappropriate collection for clinical studies prevent a 
significant introduction of biomarkers in the clinical practice.  
Our laboratory, thanks to the possibility to access the fresh and archival samples from 
hospitals, can investigate these technical problems directly on clinical material, and can use 
them in several molecular analysis on clinical case studies. My PhD thesis is connected 
with this line of research. The thesis can be divided into three parts. 
  
1. The first part is focused on the validation of alternative molecular methods of RNA 
extraction and PCR product detection for expression analysis directly in biological fluids 
and especially in urine samples.  
• We developed an experimental spin column-based RNA extraction kit that, because of 
its higher sensitivity and efficiency, could be able to replace the more time-consuming 
guanidinium-based protocol.  
• We found that it can be used also as a more economic alternative to the commercial 
silica-based kit. These evidences could make our experimental prototype a valid 
approach for the standardized diagnostics.  
• The next step involved the validation of a colorimetric approach that could overcome 
the problems associated to the use of radioactive material for PCR product detection 
after a conventional end-point PCR. We found that the so-called ELOSA method, due 
to its high sensitivity at low mRNA concentrations, may represent a good substitute for 
the isotope-based approach in gene expression analysis. Technical limitations 
connected with the narrow dynamic range of this detection approach and the rapid 
target gene-dependent expiration of probes make further experiments to validate its use 
in clinical practice necessary. 
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2. The second part of my thesis is developed in the context of  the European project called 
“Archive tissues: improving molecular medicine research and clinical practice-
IMPACTS”. My work is focused on the exploration and optimization of several molecular 
approaches for gene expression analysis (from pre-analytical to analytical treatment of 
FFPE) that can limit the use of archival tissues in clinical practice.   
• Formalin fixation has detrimental effects on both quantity and quality of RNA. With 
prolonged fixation, a rapid decrement in RNA yield is observed, followed by a 
progressive RNA degradation that involves both rRNA and mRNA species. These 
effects on RNA are confirmed by gene expression experiments, in which the levels of 
degradation are time-dependent and either prevent detection of low expressed genes or 
alter significantly the quantitative ratios between different target mRNA. Therefore, 
when formalin is used for fixation, a rigorous normalization with the proper set of 
HKGs is required. Alcoholic fixatives (FineFIX and methacarnoy) are quantitatively 
and qualitatively more conservative than formalin. This is more evident for mRNA, 
while rRNA seems to undergo a rapid degradation. This is evident from the gene 
expression analysis, where alterations of gene expression ratios are not time-dependent. 
For this reason they can be considered the best choice when small clinical samples 
have to be used for a reliable gene expression analysis. 
• The most accurate method for total RNA quantification is Nanodrop. Its results are in 
line with those of the conventional spectrophotometer but it’s more sensitive, practical 
and reproducible. Furthermore, it’s also more accurate for quality assessment. These 
are very important requirements when a large number of clinical sample have to be 
quantified. 
• The use of the smear analysis by Agilent Bioanalyzer and the endpoint RT-PCR on 
fragments of increasing length is recommended for the detection of RNA degradation 
levels when tissues are fixed both in formalin and alcoholic fixatives. For formalin 
fixation, the approaches that base their analysis on the evaluation of the rRNA ratio are 
not valid because the good quality of rRNAs overestimate the real accessibility of 
mRNA for the subsequent gene expression analysis. Conversely, for alcoholic fixation 
the rRNA ratio method may underestimate the effective availability of mRNA for 
successful amplifications. 
• DNase treatment followed by heat inactivation can be used as a valid alternative for the 
more classical extraction-based approach. It gives good results in gene expression 
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analysis but avoids the loss of RNA during the extraction step. It’s the best choice 
when small amounts of RNA are available. 
• The use of MMLV enzyme with random primers (both 6-mers and 15-mers) at high 
concentration represent the most efficient and sensitive combination for the reverse 
transcription step. This is an optimal method when using small clinical samples  
because the same cDNA solution can be used for more than one amplification. 
• SybrGreen chemistry can be used as a substitute of the TaqMan probe-based approach 
for gene expression analysis because of its high sensitivity and reproducibility. 
However, when very low expression levels must be detected (Ct>34) TaqMan 
approach still remain the best choice. 
• The further inter-laboratory validation and standardization of these molecular 
approaches for gene expression analysis in archival tissues will be essential for the 
definition of the European guidelines for a reliable and reproducible use of molecular 
methods in clinical practice. 
 
3. The third part of my thesis is focused on the clinical application of molecular approaches 
for quantification of candidate biomarkers in two archival case studies.  
• In the breast cancer case study we found that a panel of 7 genes is associated to 
patients’ survival, while  the combination of two couples of genes is able to define 
short and long living cohorts of patients. In particular, we found that RB and CDK2 on 
one side and CK8 and HER2 on the other may affect the clinical course of the disease 
in 56% of patients. Groups characterised by low RB and high CDK2 as with low CK8 
and high HER2 have a higher risk of recurrences and death in five years. The 
identification of these subgroups of patients with higher risk of early relapse could 
have further involvement in the selection of the cases to submit to therapy against 
HER2 or CDK2 as possible therapy target. 
• In the rare adrenal gland tumor case study, composed by 34 specimens, we found that 
adenoma and carcinoma are molecularly different, and these differences are determined 
by the presence of the angiogenetic receptors. Pheochromocytoma seems to be 
molecularly more similar to the adrenal carcinoma. The fine equilibrium among the 
angiogenetic factors has a key role in the maintenance of a physiologic angiogenetic 
pattern only in peritumoral tissues. In the progression towards malignancy this 
equilibrium is lost, but the two receptors remain important in tumor malignancy. 
Tumoral neoangiogenesis seems to be connected to a deregulation of the VEGF 
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pathway only in the adrenocortical carcinoma, while in the other tumoral groups it 
seems to play a secondary role.  
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